|
BLOOD-RELATED
DISEASES/DISORDERS
Cost Studies
|
PBR1 |
COST OF KALIUM
SUPPLEMENTATION WITH KALIPOZ PROLONGATUM OR KALDYUM FROM PAYER
PERSPECTIVE IN POLAND
Kawalec P1, Glogowski C2,
Krzyzanowska A3
1 Jagiellonian University, Kraków, Malopolska,
Poland; 2 GlaxoSmithKline Pharmaceuticals S.A,
Warszawa, Poland; 3 GlaxoSmithKline Pharmaceuticals
S.A, Warszawa, Poland, WARSZAWA, Poland |
|
PBR2 |
ECONOMIC
IMPACT OF ANTIHEMOPHILIC FACTOR (RECOMBINANT),
PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM) IN PATIENTS WITH
HEMOPHILIA A
Chung KC1, Mueller L2
1Baxter BioScience, Westlake Village, CA, USA; 2
MORE Baxter Bioscience, Deerfield, IL, USA |
|
PBR3 |
ECONOMIC
MODELING OF ANTIHEMOPHILIC FACTOR (RECOMBINANT),
PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM): VALUE OF POTENTIAL VIRAL
TRANSMISSION REDUCTION DUE TO PLASMA/ALBUMIN-FREE FORMULATION
Sclar DA1, Skaer TL1, Robison LM1,
Evans MA1,
Chung KC2, Poulios NS2
1 Washington State University, Pullman, WA, USA;
2 Baxter BioScience, Westlake Village, CA, USA |
|
PBR4 |
COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS PREPARED WITH
PATHOGEN INACTIVATION TREATMENT IN JAPAN
Staginnus U1, Russell S2, Corash
LM3
1 Premor Associates, New York, NY, USA; 2
Premor Associates, Madrid, Spain; 3 Cerus
Corporation, Concord, CA, USA |
|
PBR5 |
COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM
PROPHYLAXIS WITH FONDAPARINUX IN MAJOR ORTHOPAEDIC SURGERY IN
SWITZERLAND
Sendi P1, Leuppi JD2
1 Institute for Clinical Epidemiology, University
Hospital, Basel, Switzerland; 2 Peumology, University
Hospital, Basel, BS, Switzerland |
|
PBR6 |
ISAM:INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT. THE
ITALIAN EXPERIENCE
Attinà G1, Baudo F2, Lopatriello S3,
Pengo V4, Poli D5
1 AstraZeneca, Milano, Italy; 2 Ospedale
Niguarda-Cà granda-, Milano, Italy; 3 Pbe Consulting
S.r.L, Verona, Italy; 4 Università di Padova, Padova,
Italy; 5 Azienda Ospedaliera Careggi, Firenze, Italy |
Quality of
Life/Utility/Preference Studies
|
PBR8 |
PHYSICIANS’ AND
PHARMACISTS’ PREFERENCES FOR HEMOPHILIA TREATMENT EVALUATED BY
CONJOINT ANALYSIS
Scalone L1, Monzini MS1, Villa M2,
Gringeri A3, Mannucci PM3, Mantovani LG1
1 University of Milan, Milan, Italy; 2
National Research Council – Institute of Biomedical
Technologies, Segrate (Milano), Italy; 3 University
of Milan and IRCCS Maggiore Hospital, Milan, Italy |
|
PBR9 |
ASSESSING
HEALTH-RELATED QUALITY OF LIFE IN ROMANIAN HAEMOPHILIACS
Mihailov D1, Lippert BM2, Serban M3
1 Children’s Hospital, Timis, Romania; 2
MERG GmbH, Medical Economics Research Group, Munich, Germany;
3 University of Medicine and Pharmacy “Victor Babes”,
Timis, Romania |
|
PBR10 |
ESTABLISHING
HEMOPHILIA PATIENTS’ PREFERENCES IN PROPHYLAXIS: A CONJOINT
ANALYSIS PILOT STUDY
Monzini MS1, Gringeri A2, Scalone
L1, Villa M3, Mannucci PM2,
Mantovani LG1
1 University of Milan, Milan, Italy; 2
University of Milan and IRCCS Maggiore Hospital, Milan, Italy;
3 National Research Council – Institute of Biomedical
Technologies, Segrate (Milano), Italy |
|
PBR11 |
QUALITY OF LIFE
IS ASSOCIATED TO ORTHOPEDIC STATUS IN HEMOPHILIACS WITH
INHIBITORS
Scalone L1, Gringeri A2, Mannucci
PM3, Mantovani LG1
1 Center of Pharmacoeconomics, University of Milan,
Milan, Italy; 2 Department Internal Medicine Maggiore
Hospital, University of Milan, Milan, Italy; 3
University of Milan, Milan, Italy |
|
PBR12 |
CLINICAL AND
SOCIO-DEMOGRAPHIC CHARACTERISTICS INFLUENCE PATIENTS’
PREFERENCES TOWARDS HEMOPHILIA TREATMENT
Monzini MS1, Gringeri A2, Scalone
L1, Mannucci PM2, Mantovani LG1,
Villa M3
1 University of Milan, Milan, Italy; 2
University of Milan and IRCCS Maggiore Hospital, Milan, Italy;
3 National Research Council – Institute of Biomedical
Technologies, Segrate (Milano), Italy |
DIABETES
Clinical Outcomes
Studies
|
PDB1 |
ASSOCIATION OF
PATIENTS’ KNOWLEDGE AND ADHERENCE TO MEDICAL ADVICE TO GLYCAEMIC
CONTROL IN THE MANAGEMENT OF DIABETES MELLITUS
Lee VW, Sin KK, Yung MS, Li MK, Chan TY
The Chinese University of Hong Kong, Shatin, Hong Kong |
Cost Studies
|
PDB2 |
EVALUATION OF
IMPROVED UTILITY ESTIMATES IN COST EFFECTIVENESS ANALYSIS OF
MULTIPLE COMPLICATIONS IN TYPE-2 DIABETES
McEwan P1, Peters JR2, Currie CJ2
1 University Hospital of Wales, Cardiff, Wales, UK;
2 Cardiff Research Consortium, Cardiff, Wales, UK |
|
PDB3 |
COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR COMPARED TO NPH
INSULIN IN PATIENTS WITH TYPE-2 DIABETES IN THE UK
Smith I1, Palmer AJ2, Roze S2,
Kennedy-Martin T1
1 Novo Nordisk UK, Crawley, UK; 2 CORE
Center for Outcomes Research, Binningen/Basel, Switzerland |
|
PDB4 |
THE DIABETES
TYPE-2 COST PREDICTORS
Niewada M1, Glogowski C2, Latek M3,
Pietrasik A4, Kamiñski B3, Gierczynski J2,
Krzyzanowska A2
1 Medical University of Warsaw, Warsaw, Poland;
2 GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland;
3 Warsaw School of Economics, Warsaw, Poland; 4
Medical University of Warsaw, Department of Cardiology, Warsaw,
Poland |
|
PDB5 |
COMMUNITY
EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS IN GERMANY
Häussler B1, Berger U1, Mast O2
1 IGES Institut für Gesundheits- u. Sozialforschung,
Berlin, Germany; 2 Hestia Health Care GmbH |
|
PDB6 |
THE COST OF
TYPE-2 DIABETES IN UKRAINE
Zaliska ON, Boyko AI
Lviv state medical university, Lviv, Ukraine |
|
PDB7 |
LONG TERM COST
EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS INSULIN
GLARGINE IN INSULIN NAÏVE PATIENTS WITH TYPE-2 DIABETES POORLY
CONTROLLED ON ORAL HYPOGLYCEMIC AGENTS IN DANISH, DUTCH,
FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH, SWEDISH AND UK
SETTINGS.
Lammert M1, Palmer AJ2, Roze S2,
Minshall ME3, Valentine WJ2, Nicklasson L4
1 Novo Nordisk A/S, Bagsvaerd, Denmark; 2
CORE Center for Outcomes Research, Binningen/Basel, Switzerland;
3 CORE-USA, Fishers, IN, USA; 4 Novo
Nordisk Pharmaceuticals, Inc, Princeton, NJ, USA |
|
PDB8 |
WILL IRBESARTAN
LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN
HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?
Pirk O1, Ratzmann KP2, Carels J3,
Bramlage P4, Kirch W4
1 Fricke & Pirk GmbH, Nuremberg, Germany; 2
Diabetische Schwerpunktpraxis, Berlin, Germany; 3
Sanofi-Synthelabo, Berlin, Germany; 4 Medizinische
Fakultaet Carl Gustav Carus der Technischen Universitaet
Dresden, Dresden, Germany |
|
PDB9 |
THE VALUE OF
ORAL MONOTHERAPY ALTERNATIVES IN THE FIRST-LINE TREATMENT OF
TYPE-2 DIABETES MELLITUS
Tilden D1, Stynes G1, Swift M2,
Cockle S1, Haycox A3,
Aristides M1
1 M-TAG Limited, Hammersmith, UK; 2 Takeda
UK Limited, High Wycombe, UK; 3 University of
Liverpool, Liverpool, UK |
|
PDB10 |
THE
COST-EFFECTIVENESS OF PIOGLITAZONE IN COMBINATION WITH METFORMIN
IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SCOTLAND
Stynes G1, Tilden D1, Swift M2,
Cockle S1, Haycox A3,
Aristides M1
1 M-TAG Limited, Hammersmith, UK; 2 Takeda
UK Limited, High Wycombe, UK; 3 University of
Liverpool, Liverpool, UK |
|
PDB11 |
PHARMACOECONOMIC ASPECTS OF USE OF INSULIN GLARGINE IN TREATMENT
OF DIABETES MELLITUS TYPE 2 (DM T2) IN RUSSIA
Suntsov YI, Dedov II, Komarova VP, Vedeneeva LF
Endocrinology Research Center, Moscow, Russia |
|
PDB12 |
COSTS OF TYPE-2
DIABETES MELLITUS: A COMPARISON BETWEEN DIABETIC AND
NON-DIABETIC SUBJECTS
Perelli Cippo P, Scalone L, Mantovani LG
University of Milan, Milan, Italy |
|
PDB13 |
ECONOMIC
EVALUATION OF THE STEPPED VERSUS ORDINARY CARE FOR PREVENTION OF
TYPE-2 DIABETES IN THE JDPP: JAPAN DIABETES PREVENTION PROGRAM
Yanagisawa S1, Shimaya M1, Nakahara N1,
Kamae I1, Kuzuya H2
1 Kobe University, Kobe, Japan; 2 National
Hospital Organization Kyoto Medical Center, Kyoto, Japan |
|
PDB14 |
COST-EFFECTIVENESS OF MONO- AND COMBINATION THERAPY WITH
PIOGLITAZONE COMPARED TO GLICLAZIDE IN PATIENTS WITH
TYPE-2-DIABETES MELLITUS FROM A GERMAN STATUTORY HEALTH CARE
PERSPECTIVE
Schramm W1, Neeser K2, Mast O2,
Lübben G3, Lütke A4
1 Eumedes, Krailling, Germany; 2 IMIB –
Institute for Medical Informatics and Biostatistics, Basel,
Switzerland; 3 Takeda Pharma GmbH, Aachen, Germany;
4 Med. In. Form, Scharbeutz, Germany |
|
PDB15 |
A
COST-EFFECTIVENESS ANALYSIS OF SWITCHING TYPE-2 DIABETES
PATIENTS FROM IMMEDIATE-RELEASE METFORMIN (GLUCOPHAGE®) TO A NEW
EXTENDED-RELEASE FORMULATION OF METFORMIN (GLUCOPHAGE®XR)
Renaudin C1, Roze S2, Valentine WJ2,
Palmer AJ2
1 Merck Santé, Lyon, France; 2 CORE Center
for Outcomes Research, Binningen/Basel, Switzerland |
|
PDB16 |
EFFECT OF
PATIENT EDUCATION IN TYPE-2 DIABETES OVER 10 YEARS BASED ON A
PROSPECTIVE DIABETES MODEL IN THE PROVINCE OF STYRIA, AUSTRIA
Habacher W1, Palmer AJ2, Pieber TR1,
Rakovac I1, Fritz C1, Gfrerer R1,
Roze S2
1 Joanneum Research, Graz, Austria; 2 CORE
Center for Outcomes Research, Binningen/Basel, Switzerland |
|
PDB17 |
ABSOLUTE AND
INCREMENTAL EFFECTS OF THERAPY-SWITCHING THRESHOLDS ON THE
COST-EFFECTIVENESS OF TREATMENTS FOR OBESE TYPE-2 DIABETES
PATIENTS IN GERMANY
Shearer A1, Bagust A1, Schoeffski O2,
Liebl A3,
Goertz A4
1 University of York, York, UK; 2
University Erlangen-Nuremberg, Nuremberg, Germany; 3
Diabetes Stoffwechselzentrum Tegernsee, Rottach-Egern, Germany;
4 GlaxoSmithKline, Munich, Germany |
|
PDB18 |
SEARCHING FOR
DIABETES MELLITUS (DM) IN PRIMARY CARE – IT IS GOOD
VALUE-FOR-MONEY IN POLAND? (COST OF DIAGNOSING DIABETES MELLITUS
IN PRIMARY CARE CONDITION IN POLAND)
Sieradzki J1,
Faluta T2, Czech M2, Szczepañski M2,
Wilkins A2, Pachocki R2
1 Jagiellonian University in Krakow, Krakow, Poland;
2 Servier Polska, Warsaw, Poland |
|
PDB19 |
COST OF
HOSPITAL ADMISSIONS FOR CARDIOVASCULAR DISEASE OVER FIVE YEARS
IN PATIENTS WITH DIABETES MELLITUS
O’Brien JA, Duran P, Pitoniak-Morse CA, Caro JJ
Caro Research Institute, Concord, MA, USA |
|
PDB20 |
COST AND
OUTCOMES OF THE DIABETES CLINIC IN A COMMUNITY HOSPITAL, MAE
HONG SON, THAILAND
Ploylearmsang C1, Thakamphu L2
1 Mahasarakham University, Mahasarakham,
Mahasarakham, Thailand; 2 Lampang Provincial Public
Health Office, Lampang, Lampang, Thailand |
|
PDB21 |
ECONOMIC VALUE
OF ACARBOSE TREATMENT IN PERSONS WITH IMPAIRED GLUCOSE TOLERANCE
(IGT) FOR THE GERMAN HEALTH CARE SYSTEM
Evers T1, Lüddeke HJ2, Liebl A3,
Kotowa W4, Maclaine G5
1 Bayer Vital GmbH, Leverkusen, Germany; 2
Diabetische Schwerpunktpraxis, Munich, Germany; 3
Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany; 4
Fricke & Pirk GmbH, Nuremberg, Germany; 5 Bayer plc,
Uxbridge, UK |
|
PDB22 |
COST-EFFECTIVENESS ANALYSIS OF THE DIABETES PREVENTION PROGRAM
IN A SPANISH SETTING
Palmer AJ1, Roze S1, Valentine WJ1,
Renaudin C2
1 CORE Center for Outcomes Research, Binningen/Basel,
Switzerland; 2 Merck Santé, Lyon, France |
|
PDB23 |
COST-EFFECTIVENESS OF ACARBOSE FOR THE MANAGEMENT OF IMPAIRED
GLUCOSE TOLERANCE IN SWEDEN
Quilici S1, MacLaine G2, Hutka M1,
Chancellor J1, McGuire A3
1 Innovus Research (UK) Ltd, High Wycombe, UK; 2
Bayer plc, Uxbridge, UK; 3 London School of
Economics, London, UK |
|
PDB34 |
A
PHARMACOECONOMIC ANALYSIS OF THE USE OF AN INTENSIVE STRATEGY
FOR TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2 (DM T2)
Smirnova OM1,
Komarova VP2
1 Endocrinology Research Center, Moscow, Russia;
2 Aventis Pharma, Moscow, Russia |
Quality of
Life/Utility/Preference Studies
|
PDB24 |
CONTINGENT
VALUATION OF AN INHALED DELIVERY SYSTEM FOR INSULIN
Sadri H, MacKeigan L, Einarson TR, Leiter LA
University of Toronto, Toronto, ON, Canada |
|
PDB25 |
QUALITY OF LIFE
IN SUBJECTS WITH AND WITHOUT TYPE-2 DIABETES MELLITUS
Perelli Cippo P, Scalone L, Micheletti S, Mantovani LG
University of Milan, Milan, Italy |
|
PDB26 |
THE IMPACT OF
VASCULAR EVENTS ON HEALTH-RELATED UTILITY IN PATIENTS WITH AND
WITHOUT TYPE-2 DIABETES
Currie CJ1, Peters JR1, Morrissey
M1, Bergenheim K2, McEwan P3
1 Cardiff Research Consortium, Cardiff, Wales, UK;
2 AstraZeneca, Molndal, Sweden; 3
University Hospital of Wales, Cardiff, Wales, UK |
Health Policy
Studies
|
PDB27 |
A
MULTIDIMENSIONAL HEALTH CARE INTERVENTION ASSESSMENT: THE
CO-ORDINATED DIABETES HEALTHCARE NETWORK
Da Costa E1,
Jasso Mosqueda G2, Lemasson H2,
Roche B1, Guerraoui A1, Aguilera D1,
Chicoye A3
1 Centre hospitalier de Vichy, Vichy, Auvergne,
France; 2 AREMIS Consultants, Member of Aegisnet,
Neuilly Sur Seine, Ile de France, France; 3 Aremis
Consultants, Member of Aegisnet |
|
PDB28 |
VALIDATION OF
ORAL ANTIDIABETIC DRUGS PRESCRIPTIONS: THE VIEWS OF PRIMARY CARE
PHYSICIANS
Gutierrez L1, Magaz S1, Badia X2
1 Health Outcomes Policy and Economics, Barcelona,
Spain; 2 Health Outcomes Research Europe Group,
Barcelona, Spain |
|
PDB29 |
THERAPY CHANGE
AND PROGRESSION TO INSULIN USE AMONG TYPE-2 DIABETIC PATIENTS
NEWLY TREATED WITH SULFONYLUREA (SU) OR METFORMIN (MF)
MONOTHERAPY
Kerasidou O1, Yin D2, Lyu R2
1 The University of Sheffield, Sheffield, UK; 2
Merck & Co., Inc, Whitehouse Station, NJ, USA |
|
PDB30 |
DRUG
UTILIZATION OF GLITAZONES IN ITALY
Arpinelli F, Visona G
GlaxoSmithKline S.p.A, Verona, Italy |
|
PDB31 |
COMPARISON OF
BLOOD PRESSURE AND ATTRIBUTABLE HEALTHCARE COSTS BY
DIHYDROPYRIDINE VS NONDIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER
INITIATED FOR HYPERTENSION IN DIABETES MELLITUS PATIENTS, AND
MONITORING OF RENAL PARAMETERS
Barron JJ, Al-Zakwani IS, Iarocci TP, Groesbeck JM
HealthCore, Inc, Wilmington, DE, USA |
|
PDB32 |
LONG-TERM
DIABETES COMPLICATIONS: INFLUENCE OF DELAY IN STARTING
INTENSIFIED THERAPY AND OF PATIENT RATES TREATED TO TARGET A1C.
ANALYSES WITH THE DIABETES MELLITUS MODEL (DMM)
Bergemann R1, Huppertz E2, Mueller
E1, Maxion-Bergemann S1
1 Analytica International, Loerrach, Germany; 2
Aventis Pharma Deutschland GmbH, Bad Soden, Germany |
Methods
|
PDB33 |
EAGLE –DIABETES
MODEL: BASIC FEATURES AND INTERNAL VALIDATION OF SIMULATING
LONG-TERM DIABETIC OUTCOMES AND RELATED COSTS
Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S,
Bergemann R
Analytica International, Loerrach, Germany |
EYE, EAR & SKIN
DISEASES/DISORDERS
Clinical Outcomes
Studies
|
PES1 |
ASSOCIATION
BETWEEN DIMINISHED ACTIVITY OF DAILY LIVING AND VISUAL
IMPAIRMENT IN SUBJECTS LIVING IN THE COMMUNITY: RESULTS FROM A
FRENCH NATIONAL SURVEY
Brézin A1, Lafuma A2, Fagnani F2,
Mesbah M3,
Berdeaux G4
1 Hopital Cochin, Paris, France; 2 Cemka,
Bourg-La-Reine, France; 3 Université de Bretagne-Sud,
Vannes, France; 4 Alcon, Rueil-Malmaison, France |
|
PES2 |
ASSOCIATION
BETWEEN MORTALITY AND VISUAL IMPAIRMENT ESTIMATED FROM A FRENCH
NATIONAL SURVEY
Brézin A1, Lafuma A2, Fagnani F2,
Mesbah M3,
Bordeaux G4
1 Hopital Cochin, Paris, France; 2 Cemka,
Bourg-La-Reine, France; 3 Université de Bretagne-Sud,
Vannes, France; 4 Alcon, Rueil-Malmaison, France |
|
PES3 |
ANALYSIS OF
CLINICAL EFFICACY OF LATANOPROST VS. THE MOST FREQUENT TREATMENT
PATTERN FOR PRIMARY OPEN ANGLE GLAUCOMA (POAG) AND OCULAR
HYPERTENSION (OH) IN POLAND
Walczak J1, Pajor A1, Kaczor M1,
Wcislo J2
1 Arcana Institute, Krakow, Poland; 2
Pfizer, Warsaw, Poland |
|
PES4 |
EFFECT OF
CIRCADIAN INTRA-OCULAR PRESSURE VARIATIONS ON THERAPEUTIC
DECISION MAKING: A MODELING APPROACH BASED ON A RANDOMIZED
CLINICAL TRIAL
Dubiner HB1,
Berdeaux G2
1 Clayton eye center, Morrow, GA, USA; 2
Alcon, Rueil-Malmaison, France |
Cost Studies
|
PES5 |
A
COST-EFFECTIVENESS ANALYSIS OF LATANOPROST IN THE TREATMENT OF
OPEN ANGLE GLAUCOMA IN SPAIN
Soto J, De Miguel V
Pfizer S.A, Alcobendas, Madrid, Spain |
|
PES6 |
COST
EFFECTIVENESS OF LATANOPROST IN FIRST LINE TREATMENT OF PRIMARY
OPEN ANGLE GLAUCOMA IN THE UK
Gosden T1,
Costello S2, Orme ME2, Howard P2,
Dooley JA1
1 Pfizer Ltd, Tadworth, UK; 2 Heron
Evidence Development, Letchworth Garden City, UK |
|
PES7 |
A
PHARMACOECONOMIC ANALYSIS OF THE FIXED COMBINATION
LATANOPROST/TIMOLOL VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT
OF PATIENTS WITH GLAUCOMA IN SPAIN
Soto J, De Miguel V
Pfizer S.A, Alcobendas, Madrid, Spain |
|
PES8 |
RESOURCE
UTILIZATION OF END-STAGE GLAUCOMA PATIENTS RECEIVING LOW VISION
CARE: A US MULTI-SITE RETROSPECTIVE STUDY
Williams RT1, O’Connell WF2, Walt J3,
Siegartel LR4, Katz LM4,
Doyle JJ4
1 Deicke Center for Visual Rehabilitation, Wheaton,
IL, USA; 2 State College of Optometry, State
University of New York, New York, NY, USA; 3 Allergan
Inc. USA, Irvine, CA, USA; 4 Analytica International,
New York, NY, USA |
|
PES9 |
PREVALENCE OF
FRACTURES AND DEPRESSION AND THEIR ASSOCIATION WITH BLINDNESS IN
A MEDICARE POPULATION WITH PRIMARY OPEN-ANGLE GLAUCOMA: AN
EXAMINATION OF BLINDNESS-RELATED COMORBIDITIES AND THEIR COSTS
Spalding JR1, Coleman A2, Fei Y2,
Buchholz P3,
Globe D4
1 University of Southern California, School of
Pharmacy, Los Angeles, CA, USA; 2 David Geffen School
of Medicine, Los Angeles, CA, USA; 3 Allergan R&D
Europe, Ettlingen, Germany; 4 University of Southern
California, Los Angeles, CA, USA |
|
PES10 |
A NATION-WIDE
ESTIMATE OF NON-MEDICAL SOCIO-ECONOMIC CONSEQUENCES ATTRIBUTABLE
TO VISUAL IMPAIRMENT IN FRANCE: A SOCIETAL PERSPECTIVE
Lafuma A1, Brézin A2, Fagnani F1,
Mesbah M3,
Berdeaux G4
1 Cemka, Bourg-La-Reine, France; 2 Hopital
Cochin, Paris, France; 3 Université de Bretagne-Sud,
Vannes, France; 4 Alcon, Rueil-Malmaison, France |
|
PES11 |
ESTIMATION OF
NATIONWIDE COSTS OF ANNUAL ASSISTANCE ATTRIBUTABLE TO VISUAL
IMPAIRMENT, FROM AN ACTIVITY OF DAILY LIVING QUESTIONNAIRE
Berdeaux G1, Lafuma A2, Mimaud V2
1 Alcon, Rueil-Malmaison, France; 2 CEMKA,
Bourg la Reine, France |
|
PES12 |
NON-MEDICAL
COSTS RELATED TO VISUAL IMPAIRMENT IN FOUR EUROPEAN COUNTRIES
(FRANCE, GERMANY, ITALY AND THE UK)
Lafuma A1, Lopatriello S2, Hieke K3,
Hutchinson J4, Mimaud V1,
Berdeaux G5
1 CEMKA, Bourg la Reine, France; 2
PBE-Consulting, Verona, Italy; 3 Neos Health,
Binningen, Switzerland; 4 Fourth Hurdle Consulting
Ltd, London, UK; 5 Alcon France SA, Rueil-Malmaison,
France |
|
PES13 |
A COST
MINIMISATION ANALYSIS OF CUSTOM PAK® FOR CATARACT SURGERY
Lafuma A1, Smith AF2
1 CEMKA, Bourg la Reine, France; 2
University of Oxford, Oxford, UK |
|
PES26 |
ANALYSIS OF
RUSSIAN PHARMACEUTICAL MARKET OF ANTI-GLAUCOMA MEDICINES IN THE
PERIOD 2000-2003
Kuroyedov AV
Mandryka 2nd Central Military Clinical Hospital,
Moscow, WA, Russia |
Quality of
Life/Utility/Preference Studies
|
PES14 |
RESPONSIVENESS
OF SELF-REPORTED VISUAL FUNCTIONING IN AGE –RELATED MACULAR
DEGENERATION (AMD) PATIENTS TO GENERAL HEALTH AND CHANGES IN
VISUAL ACUITY IN A PHASE I/II RANDOMIZED CONTROLLED TRIAL OF
LUCENTIS™ (RANIBIZUMAB; RHUFAB V2)
Globe D1, Tonnu IQ1, Chang TS1,
Fine J2
1 University of Southern California, Los Angeles, CA,
USA; 2 Genentech, Inc, South San Francisco, CA, USA |
|
PES15 |
IMPACT OF ATOPIC DERMATITIS ON PARENTΨS QUALITY OF LIFE AND USE OF
DIRECT RESOURCES IN PATIENTS BETWEEN 2 AND 12 YEARS OLD. DAES
STUDY
Espinosa C1, García A2,
García-Patos V3, Hachero JG4, Polanco I5,
Rodrigo C6, Zambrano A7, Figueras M1,
Díaz JM1
1 Novartis Farmacéutica S.A, Barcelona, Spain; 2
Hospital de la Princesa, Madrid, Spain; 3 Hospital
Vall D’Hebrón, Barcelona, Spain; 4 Hospital Virgen de
la Macarena, Sevilla, Spain; 5 Hospital La Paz,
Madrid, Spain; 6 Hospital Germans Trias I Pujol,
Barcelona, Spain; 7 Hospital Niño Jesús, Madrid,
Spain |
|
PES16 |
SCALING
PROPERTIES OF THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)
McKenna SP, Meads DM, Doward LC
Galen Research, Manchester, UK |
|
PES17 |
LIVING WITH A
DERMATOSIS: A NATIONAL SURVEY OF QUALITY OF LIFE IN BELGIUM
Lambert J1, De la Brassinne M1,
Myon E2, Martin N3, Monnier F4,
Weckx H4, Taieb C2
1 Royal Belgium Society of Dermatology, Brussels,
Belgium; 2 Health Economics & Quality of Life Dept,
Boulogne-Billancourt, France; 3 IRPF,
Boulogne-Billancourt, France; 4 AVENE Dermatological
Laboratories, Brussels, Belgium |
|
PES18 |
INTERPRETATION
OF SCORES ON THE PSORIASIS INDEX OF QOL (PSORIQOL)
McKenna SP1, Meads DM1, Backhouse
ME2
1 Galen Research, Manchester, UK; 2
Novartis Pharma AG, Basel, Switzerland |
|
PES19 |
SENSITIVE SKIN:
QUALITY OF LIFE IMPACT
Misery L1,
Myon E2, Martin N2, Verriere F3,
Nocera T3, Taieb C2
1 Dermatological Clinic, Brest, France; 2
IRPF, Boulogne-Billancourt, France; 3 Avene
Dermatological Laboratories, Lavaur, France |
|
PES20 |
SUNBURNS AND
QUALITY OF LIFE
Guitera P1, Dubertret L1, Myon E2,
Nocera T3, Perez N3, Martin N2,
Taieb C2
1 Hopital Saint Louis, Paris, France; 2
IRPF, Boulogne-Billancourt, France; 3 Avene
Dermatological Laboratories, Lavaur, France |
|
PES21 |
HAIR LOSS,
QUALITY OF LIFE IMPACT
Taieb C1, Macy G2, Sibaud V2,
Martin N1, Myon E1
1 IRPF, Boulogne-Billancourt, France; 2
DUCRAY Dermatological Laboratories, Lavaur, France |
|
PES22 |
HAIR LOSS,
EPIDEMIOLOGICAL APPROACH
Taieb C1, Macy G2, Sibaud V2,
Martin N1, Myon E1
1 IRPF, Boulogne-Billancourt, France; 2
DUCRAY Dermatological Laboratories, Lavaur, France |
Health Policy
Studies
|
PES23 |
SUN SENSITIVITY
AND PERSONAL BEHAVIOURS
Guitera P1, Dubertret L1, Myon E2,
Perez N3, Nocera T3, Martin N2,
Taieb C2
1 Hopital Saint Louis, Paris, France; 2
IRPF, Boulogne-Billancourt, France; 3 Avene
Dermatological Laboratories, Lavaur, France |
|
PES24 |
IMPACTED
CERUMEN: A LITERATURE REVIEW
Guest JF1, Greener MJ1, Smith AF2
1 Catalyst Health Economics Consultants, Middlesex,
UK; 2 University of Oxford, Oxford, UK |
Methods
|
PES25 |
ASSOCIATION
BETWEEN VITAMIN SUPPLEMENTS USAGE AND PRESENCE OF AGE-RELATED
MACULAR DEGENERATION IN A LATINO POPULATION ADJUSTING FOR
SELECTION BIAS USING PROPENSITY SCORES
Bonnet PO1, Globe D1, Varma R2,
Johnson KA1
1 University of Southern California, School of
Pharmacy, Los Angeles, CA, USA; 2 University of
Southern California, Keck School of Medicine, Los Angeles, CA,
USA |
GASTROINTESTINAL
DISEASES/DISORDERS
Cost Studies
|
PGI1 |
ECONOMIC
EVALUATION OF ON-DEMAND MAINTENANCE THERAPY WITH PROTON PUMP
INHIBITORS IN PATIENTS WITH SYMPTOMATIC GASTROESOPHAGEAL REFLUX
DISEASE – A MONTE-CARLO ANALYSIS FOR ITALY
Hughes DA1, Marchetti M2, Colombo
GL3
1 University of Liverpool, Liverpool, Merseyside, UK;
2 IRCCS Policlinico San Matteo, Pavia, Italy; 3
S.A.V.E Studi Analisi Valutazioni Economiche, Milano, Italy |
|
PGI2 |
THE ECONOMIC
EVALUATION OF A RANDOMIZED TRIAL COMPARING ‘TEST-AND-TREAT’ WITH
PROMPT ENDOSCOPY IN PRIMARY CARE; THE HEALTH ECONOMICS OF THE
SENSE-STUDY
Klok RM1, Arents NL2, De Vries R1,
Thijs JC3, Brouwers JR1, Kleibeuker JH2,
Postma MJ1
1 University of Groningen, Groningen, Groningen,
Netherlands; 2 University Hospital Groningen,
Groningen, Groningen, Netherlands; 3 Bethesda
Hospital, Hoogeveen, Drenthe, Netherlands |
|
PGI3 |
COST-EFFECTIVENESS OF ESOMEPRAZOLE COMPARED TO PANTOPRAZOLE AND
GENERIC OMEPRAZOLE IN ENDOSCOPY POSITIVE GERD PATIENTS IN
GERMANY
Gross M1, Braun S2,
Reitberger U2, Spannheimer A2
1 Internistische Klinik Dr. Mueller, Munich, Germany;
2 Kendle International Inc, Munich, Germany |
|
PGI4 |
USE OF CAPSULE
ENDOSCOPY IN DIAGNOSING OBSCURE GASTROINTESTINAL BLEEDING:
COST–EFFECTIVENESS EVALUATION FROM A EUROPEAN PERSPECTIVE
Mueller E, Schwander B, Bergemann R
Analytica International, Loerrach, Germany |
|
PGI5 |
COSTS BENEFITS
WITH ESOMEPRAZOLE 20MG ‘ON-DEMAND’ TREATMENT IN GASTROESOPHAGEAL
REFLUX DISEASE (GERD) PATIENTS IN BELGIUM
Louis E1, Urbain D2, Deltenre M3,
Vandenhoven G4, Duquenne V4,
Schockaert B4
1 Ulg, Liège, Belgium; 2 AZ VUB, Brussel;
3 ULB, Bruxelles, Belgium; 4 NV
AstraZeneca SA, Brussels, Belgium |
|
PGI6 |
ECONOMIC
EVALUATION OF RABEPRAZOLE VS. OMEPRAZOLE IN THE CURATIVE
TREATMENT OF REFLUX OESOPHAGITIS
Colombo GL1, Caraglia M2, Casalini
S2, Nardini P2
1 S.A.V.E Studi Analisi Valutazioni Economiche,
Milano, Italy; 2 Janssen-Cilag SpA, Latina, Italy |
|
PGI7 |
COST BENEFIT
ANALYSIS OF TWO TREATMENTS FOR PATIENTS WITH CHOLEDOCHOLITHIASIS
AND CHOLECYSTOLITHIASIS
Yang MC, Lai GL
National Taiwan University, Taipei, Taiwan |
|
PGI8 |
PHARMACOECONOMIC ASPECTS OF CROHN´S DISEASE IN SLOVAKIA
Bielik J1, Hlista M2, Èernok S3
1 Slovak Society for Pharmacoeconomics, Nové Mesto
nad Váhom, Slovak Republic; 2 Hospital Trenèín,
Trenèín, Slovak Republic; 3 Hospital Nové Mesto nad
Váhom, Nové Mesto nad Váhom, Slovak Republic |
Quality of
Life/Utility/Preference Studies
|
PGI9 |
IS HELICOBACTER
PYLORI “TEST AND TREAT” A COST-EFFECTIVE MANAGEMENT APPROACH FOR
PATIENTS WITH TYPICAL REFLUX SYMPTOMS IN A POPULATION WITH A
HIGH PREVALENCE OF H. PYLORI INFECTION
You JH, Wong PL, Wu JC
The Chinese University of Hong Kong, Shatin, N.T, Hong Kong |
|
PGI10 |
HEALTH RELATED
QUALITY OF LIFE AMONG POLISH GASTROESOPHAGEAL REFLUX DISEASE
PATIENTS
Kamiñski B1,
Niewada M2, Regu³a J3, Kowalik E4
1 Warsaw School of Economics, Warsaw, Poland; 2
Medical University of Warsaw, Warsaw, Poland; 3
Institute of Oncology, Warsaw, Mazowieckie, Poland; 4
Institute of Cardiology, Warsaw, Poland |
|
PGI11 |
PSYCHOMETRIC
VALIDATION OF TWO GASTROINTESTINAL (GI)-SPECIFIC
PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN RENAL TRANSPLANT
PATIENTS WITH AND WITHOUT GI COMPLICATIONS
Kleinman L1, Bahner U2, Faull R3,
Walker R4, Prasad R5, Ambuehl P6,
Machnicki G7, Margolis MK1
1 Medtap International, Seattle, WA, USA; 2
KfH Kuratorium fur Dialyse un Nierentrasnplantation, Wurzburg,
Germany; 3 Royal Adelaide Hospital, Adelaide,
Australia; 4 The Royal Melbourne Hospital, Parkville,
Australia; 5 St. Michael’s Hospital, Toronto,
Ontario, Canada; 6 University Hospital Zurich,
Zurich, Switzerland; 7 Novartis Pharma AG, Basel,
Switzerland |
|
PGI12 |
HEALTH-RELATED
QUALITY OF LIFE AND PATIENT SELF-PERCEIVED HEALTH STATUS IN IBS
Ten Berg MJ1, Goettsch WG1, Van den Boom G2,
Smout AJPM3,
Herings RMC1
1 PHARMO Institute, Utrecht, Netherlands; 2
Novartis Pharma B.V, Arnhem, Netherlands; 3
University Medical Centre, Utrecht, Netherlands |
|
PGI13 |
EFFECT OF
TEGASEROD IN WOMEN WITH IRRITABLE BOWEL SYNDROME WITH
CONSTIPATION (IBS-C) IN SOUTH AFRICA
Schneider HR1,
Goncalves J2,
1Milpark Hospital, Parktown, South Africa; 2Novartis,
Johannesburg, South Africa |
Methods
|
PGI14 |
COST-EFFECTIVENESS EVALUATION FOR A NEW DIAGNOSTIC TEST
CONSIDERING ALSO COSTS FOR FALSE NEGATIVE AND FALSE POSITIVE
DIAGNOSES AT VARIOUS PREVALENCE RATES
Mueller E, Schwander B, Bergemann R
Analytica International, Loerrach, Germany |
INFECTION
Clinical Outcomes
Studies
|
PIN1 |
CLINICAL
PRACTICE GUIDELINE EVALUATION: NEONATAL INFECTION WITH MATERNAL
HISTORY OF PREMATURE RUPTURE OF MEMBRANE (PROM)
Srijariya W1, Ratanakorn W2,
Chamnanwanakij S2, Saeng-arun P2
1 Mahidol University, Bangkok, Thailand; 2
Phramongkutklao Hospital and College of Medicine, Bangkok,
Thailand |
Cost Studies
|
PIN2 |
COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN SUSPECTED
METHICILLIN–RESISTANT STAPHYLOCOCCUS AUREUS IN NOSOCOMIAL
PNEUMONIA IN GERMANY
Grünewald T1, De Cock E2, Sorensen S3,
Baker T3,
Resch A4, Hardewig J4, Duttagupta
S5
1 Städt. Klinikum St. Georg, Leipzig, Germany; 2
MEDTAP International Inc, London, UK; 3 MEDTAP
International Inc, Bethesda, MD, USA; 4 Pfizer GmBH,
Karlsuhe, Germany; 5 Pfizer Inc, New York, NY, USA |
|
PIN3 |
LINEZOLID FOR
THE TREATMENT OF SKIN AND SOFT-TISSUE MRSA INFECTIONS – A
COST-EFFECTIVE ALTERNATIVE TO VANCOMYCIN: EVIDENCE FROM A
MULTINATIONAL CLINICAL TRIAL
Sorensen SV1, Hollenbeak CS1, Baker TM1,
Resch A2, Duttagupta S3
1 MEDTAP International Inc, Bethesda, MD, USA; 2
Pfizer GmBH, Karlsruhe, Germany; 3 Pfizer Inc, New
York, NY, USA |
|
PIN4 |
COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS VANCOMYCIN IN
THE TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN SPAIN
Grau S1, Álvarez-Lerma F2,
De la Fuente S3, Neipp R3,
Rubio-Terres C4
1 Hospital del Mar, Barcelona, Spain; 2
Hospital del Mar; 3 Pfizer S.A. Spain, Madrid, Spain;
4 HERO Consulting |
|
PIN5 |
MEASURING
RESOURCE USE AND DIRECT COSTS IN PATIENTS WITH HEPATITIS C VIRUS
MANAGED IN A GASTROENTEROLOGY AND HEPATOLOGY SERVICE
Herdman M1, Casanovas T2,
Rodriguez Fariña E2, Rodriguez T3, Ibarz R3,
Casais L2
1 3D Health Research, Barcelona, Barcelona, Spain;
2 University Hospital of Bellvitge; 3 3D
Health Research |
|
PIN6 |
CLINICAL
EFFECTIVENESS AND COST-EFFECTIVENESS OF ANTIVIRAL COMBINATION
THERAPY WITH PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR CHRONIC
HEPATITIS C ADMINISTERED ACCORDING TO THE NEW GENOTYPE-SPECIFIC
GUIDELINES
Siebert U1, Sroczynski G1,
Aidelsburger P2, Rossol S3, Wasem J2,
Manns MP4, McHutchison JG5, Wong JB6
1 Harvard Medical School, Boston, MA, USA; 2
University of Duisburg-Essen, Duisburg-Essen, Germany; 3
University of Mainz, Ruesselsheim, Germany; 4 Medical
School of Hanover, Hanover, Germany; 5 Scripps
Clinic, La Jolla, CA, USA; 6 Tufts University School
of Medicine, Boston, MA, USA |
|
PIN7 |
COST
MINIMIZATION ANALYSIS OF ORAL VALGANCICLOVIR VS. INTRAVENOUS AND
ORAL GANCICLOVIR IN THE PREVENTION OF CYTOMEGALOVIRUS INFECTION
AND DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS
Rubio M1, Oppenheimer F2, Magaz S1,
Badia X1
1 Health Outcomes Research Europe, Barcelona,
Barcelona, Spain; 2 Hospital Clinic I Provincial de
Barcelona, Barcelona, Spain |
|
PIN8 |
ECONOMIC
EVALUATION OF HIV TREATMENTS: THE I.CO.N.A. COHORT STUDY
Merito M1, Baio G2, Bonaccorsi A3,
Pammolli F4, Riccaboni M4, Arici C5,
D’Arminio Monforte A6, Pezzotti P7,
Corsini D8
1 Sant’Anna School of Advanced Studies, Pisa, PI,
Italy; 2 University of Florence, Florence, Italy,
Italy; 3 Sant’Anna School of Advanced Studies, Italy;
4 University of Florence, Italy; 5
Ospedali Riuniti – Bergamo, Italy; 6 University of
Milan, Italy; 7 Istituto Superiore di Sanità, Italy;
8 Informa srl, Italy |
|
PIN9 |
COMPARING COSTS
AND EFFECTIVENESS OF HAART TIMING IN HIV INFECTION: EVIDENCE
FROM THE I.CO.N.A. COHORT (ON BEHALF OF THE I.CO.N.A. STUDY
GROUP)
Merito M1, Pezzotti P2
1 Sant’Anna School of Advanced Studies, Pisa, PI,
Italy; 2 Istituto Superiore di Sanità, Italy |
|
PIN10 |
COST-EFFECTIVENESS OF EXPANDED HIV SCREENING OF BLOOD DONATIONS
IN GHANA
Van Hulst M1, Vermande J2, Sagoe K3,
Bos JM4, Postma MJ2
1 University of Groningen / Martini Hospital,
Groningen, Groningen, Netherlands; 2 University of
Groningen, Groningen, Groningen, Netherlands; 3
University of Ghana Medical School, Accra, Accra, Ghana; 4
The Netherlands Vaccine Institute, Bilthoven, Utrecht,
Netherlands |
|
PIN11 |
PHARMACOECONOMIC EVALUATION OF HERD PROTECTION FOR THE
SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN SWITZERLAND
Ciuryla VT1, Siegartel LR2,
Casciano R3
1 Wyeth, Collegeville, PA, USA; 2
Analytica International, New York, NY, USA; 3
Analytica International, Lörrach, Germany |
|
PIN12 |
COST-EFFECTIVENESS OF UNIVERSAL PNEUMOCOCCAL VACCINATION FOR
INFANTS IN ITALY
Marchetti M1, Colombo GL2
1 IRCCS Policlinico San Matteo, Pavia, Italy; 2
S.A.V.E Studi Analisi Valutazioni Economiche, Milano, Italy |
|
PIN13 |
ECONOMIC
EVALUATION OF VORICONAZOLE IN THE TREATMENT OF INVASIVE
ASPERGILLOSIS IN GERMANY
Jansen J1, Kern W2,
Resch A3
1 MAPI Values, Houten, Netherlands; 2
Albert-Ludwigs-Universität, Freiburg, Germany; 3
Pfizer GmbH, Karlsruhe, Germany |
|
PIN14 |
CALCULATING THE
COST OF WOUND CARE IN A COMMUNITY SETTING IN THE UK: AN EXAMPLE
USING MODERN WOUND MANAGEMENT DRESSINGS
Orme ME1, Daniels S2
1 Heron Evidence Development, Letchworth Garden City,
UK; 2 ConvaTec UK Ltd, Ickenham, Uxbridge, UK |
|
PIN15 |
ACUTE ROTAVIRUS
GASTROENTERITIS: BURDEN OF DISEASE AND COST OF ILLNESS AMONG
YOUNG CHILDREN IN GERMANY
Hammerschmidt T, Gartner B
GlaxoSmithKline, Munich, Germany |
|
PIN16 |
ECONOMIC BURDEN
AND FACTORS INFLUENCING COSTS IN GERMAN PATIENTS HOSPITALISED
FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Decker-Burgard S1, Ehrnsperger M2,
Eichmann FRW2, Huppertz E1, Kreyenberg K2,
Reitberger U2, Roscher K1, Spannheimer A2
1 Aventis Pharma Deutschland GmbH, Bad Soden am
Taunus, Germany; 2 Kendle International Inc, Munich,
Germany |
|
PIN17 |
THE COSTS OF
SEVERE SEPSIS MANAGEMENT IN INTENSIVE CARE UNITS IN POLAND
Kübler A1, Kowalik E2, Niewada M3,
Jakubczyk M4, Lis J5
1 Wrocaw Medical University, Wrocaw, Poland; 2
Institute of Cardiology, Warsaw, Poland; 3 Medical
University of Warsaw, Warsaw, Poland; 4 Center for
operations research and econometrics, Université catholique de
Louvain, Louvain-la-Neuve, Belgium; 5 Eli Lilly,
Warsaw, Poland |
|
PIN18 |
ASSESSING THE
COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN SEVERE
SEPSIS IN POLAND
Jakubczyk M1, Kowalik E2, Niewada
M3, Kübler A4, Lis J5, Kamiñski
B6
1 Center for operations research and econometrics,
Université catholique de Louvain, Louvain-la-Neuve, Belgium;
2 Institute of Cardiology, Warsaw, Poland; 3
Medical University of Warsaw, Warsaw, Poland; 4
Wrocaw Medical University, Wrocaw, Poland; 5 Eli
Lilly, Warsaw, Poland; 6 Warsaw School of Economics,
Warsaw, Poland |
|
PIN19 |
A COMPARISON OF
COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS)
PLUS RIBAVIRIN (COPEGUS) VERSUS INTERFERON ALFA-2B PLUS
RIBAVIRIN AS FIRST TREATMENT OF CHRONIC HEPATITIS C IN THE UK
Lewis GJ1, Green J2, Patel K2,
Philips Z3
1 Roche Products Ltd, Welwyn Garden City, Herts, UK;
2 Hoffman La Roche, Nutley, NJ; 3 York
University, York, UK |
|
PIN20 |
COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND CASPOFUNGIN FOR
THE TREATMENT OF INVASIVE CANDIDA AND ASPERGILLOSIS INFECTIONS
IN SPAIN
Domínguez-Gil Hurlé A1, Martín Herranz I2,
García Vargas M3, Rejas J4
1 Department of Pharmacy, University Hospital at
Salamanca, Salamanca, Salamanca, Spain; 2 Department
of Pharmacy, Juan Canalejo Hospital, A Coruña, Spain; 3
Medical Unit, Euroclin Institute, Madrid, Spain; 4
Pfizer SA, Alcobendas, Madrid, Spain |
|
PIN21 |
COST-BENEFIT
ANALYSIS OF ANTI-INFLUENZA VACCINATION IN A PUBLIC HEALTH CARE
UNIT
Colombo GL1, Ferro A2, Vinci M3,
Zordan M2
1 S.A.V.E Studi Analisi Valutazioni Economiche,
Milano, Italy; 2 ULSS 17, Regione Veneto; 3
S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy |
|
PIN22 |
MODELLING THE
COST-EFFECTIVENESS OF ACTIVATED PROTEIN C (XIGRIS® ) TREATMENT
OF SEPTIC PATIENTS IN INTENSIVE CARE UNITS IN HUNGARY
Hoffer G1, Csomós Á2, Kardos L1,
Demeter J3, Homoki H4, Zaray L5
1 University of Debrecen, Debrecen, Hungary; 2
Markoth Ferenc County Hospital, Eger; 3 MD&B Ltd;
4 Lilly Hungaria Ltd; 5 Lilly Hungaria
Ltd, Debrecen, Germany |
|
PIN23 |
PROSPECTIVE
STUDY ON ACUTE LOWER RESPIRATORY TRACT INFECTION IN CHILDREN
YOUNGER THAN 3 YEARS IN GERMANY (PRI.DE) – ECONOMIC IMPACT OF
COMMUNITY-ACQUIRED CASES TREATED BY OFFICE-BASED PEDIATRICIANS
(PRIMARY CARE)
Ehlken B1, Berger K2, Ihorst G3,
Petersen G4, Forster J5
1 MERG, Medical Economics Research Group, Munich,
Germany; 2 MERG Medical Economics Research Group,
Munich, Germany; 3 Institute for Medical Biometry and
Medical Informatics, and Center for Clinical Trials, Freiburg,
Germany; 4 Wyeth Pharma GmbH, Münster, Germany;
5 St. Josefskrankenhaus, Freiburg, Germany |
|
PIN32 |
THE COST OF
ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING SURGERY FOR COLORECTAL
CANCER
Maselli MA1,
Scalone L2, Pezzolla F1, Demma I1,
Mantovani LG2
1 Scientific Institute of Gastroenterology,
Castellana Grotte (Bari), Italy; 2 Center of
Pharmacoeconomics, University of Milan, Milan, Italy |
Quality of
Life/Utility/Preference Studies
|
PIN24 |
IMPROVEMENT IN
PATIENT-REPORTED DEPRESSION IN HIV+ PATIENTS EXPERIENCING GRADE
2 SIDE EFFECTS AFTER SUBSTITUTION OF THEIR PROTEASE INHIBITOR
(PI)/NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) WITH
LOPINAVIR/RITONAVIR (LPV/R)
Luo MP, Shen Y, McMillan F, Sylte J, Ashraf T, Rode R
Abbott Laboratories, Abbott Park, IL, USA |
|
PIN25 |
ASSESSMENT OF
HEALTH-RELATED QUALITY OF LIFE MEASURES IN HIV AND AIDS
Clayson DJ1, Wild DJ1, Quarterman
P1, Coons SJ2, Duprat-Lomon I3,
Kubin M4
1 Oxford Outcomes Ltd, Oxford, Oxon, UK; 2
The University of Arizona College of Pharmacy, Tucson, AZ, USA;
3 Bayer Pharma, Puteaux Cedex, Paris, France; 4
Bayer HealthCare, Wuppertal, Elberfeld, Germany |
|
PIN26 |
VALIDATION OF
5-ITEM INSTRUMENT FOR ASSESSING SYMPTOM SEVERITY IN PATIENTS
WITH ACUTE BACTERIAL SINUSITIS
Taylor DC1, Norman GR2, Torrance G3,
Thompson D1, Amorosi SL1, Asche CV4,
Patel M4, Lavin B4, Ferguson B5
1 Innovus Research, Inc, Medford, MA, USA; 2
McMaster University, Hamilton, ON, Canada; 3 Innovus
Research, Inc, Burlington, ON, Canada; 4 Aventis
Pharmaceuticals, Bridgewater, NJ, USA; 5 University
ENT Specialists, Inc, Pittsburgh, PA, USA |
|
PIN27 |
WILLINGNESS TO
PAY FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (TB) IN RURAL
NEPAL: A CONTINGENT VALUATION STUDY
Paudel L1, Adhikari M1, Devkota N2
1 The University of Georgia, Athens, GA, USA; 2
Lousiana State University, Baton Rouge, LA, USA |
|
PIN28 |
ASSESSMENT OF
BODY CHANGES AND DISTRESS (ABCD) LIPODYSTROPHY QUESTIONNAIRE :
CULTURAL ADAPTATION AND PSYCHOMETRIC VALIDATION IN FRENCH
Duracinsky M1, Sereni D2, Molina
JM2, Acquadro C3, Wu A4,
Chassany O5
1 Hopital de Bicetre, Le Kremlin-Bicetre, France;
2 Hopital Saint-Louis, Paris, France; 3
MAPI Research Institute, Lyon, France; 4 Johns
Hopkins University, Baltimore, MD, USA; 5 Assistance
Publique – Hopitaux de Paris, Paris, France |
|
PIN28 |
FREQUENCY OF
POTENTIAL DRUG-DRUG INTERACTIONS WITH TRIAZOLE ANTIFUNGAL USE IN
DUTCH HOSPITAL SETTINGS
Sturkenboom MC1, Goettsch WG2,
Picelli G1, Herings RMC2
1 International Pharmacoepidemiology and
Pharmacoeconomics Research Center, Desio, MI, Italy; 2
PHARMO Institute, Utrecht, Netherlands |
Health Policy
Studies
|
PIN29 |
COSTS AND
EFFECTS OF CHLAMYDIAL SCREENING PROGRAMS: DYNAMIC VERSUS STATIC
MODELING
Welte R1, Postma MJ2, Leidl R3,
Kretzschmar M4
1 GSF – National Research Center for Environment and
Health, Neuherberg, Germany; 2 University of
Groningen, Groningen, Netherlands; 3
Ludwig-Maximilians-University, Munich, Germany; 4
RIVM – National Institute of Public Health and the Environment,
Bilthoven, 3720 BA, Netherlands |
Methods
|
PIN29 |
ECONOMIC
EVALUATION OF MENINGOCOCCAL C VACCINATION PROGRAMMES AND ITS
IMPACT ON DECISION MAKING
Welte R1, Trotter C2, Edmunds J2,
Postma MJ3, Beutels P4
1 GSF - National Research Center for Environment and
Health, Neuherberg, Germany; 2 Health Protection
Agency, London, UK; 3 University of Groningen,
Groningen, Netherlands; 4 University of Sydney,
Westmead, Australia |
METHODS
|
PMC1 |
BOOTSTRAP
CONFIDENCE INTERVALS FOR THE ANGULAR TRANSFORMED ICER: ARE MORE
SOPHISTICATED METHODS THE BETTER CHOICE?
Schweikert B1, Reitmeir P2
1 Ludwig-Maximilians-University, Munich, Germany;
2 GSF- National Research Center for Environment and
Health, Neuherberg, Germany |
|
PMC2 |
A FRAMEWORK FOR
HANDLING UNCERTAINTY AND VARIABILITY IN THE ECONOMIC EVALUATION
OF HEALTH CARE PROGRAMS.
Darbà J1, Albacar E2
1 Universitat de Barcelona, Barcelona, Spain; 2
Clinical Data Care, Barcelona, Spain |
|
PMC3 |
ECONOMIC
EVALUATION IN LATIN AMERICA
Crosbie G1,
Pritchard C2
1 OHE-IFPMA Database Ltd, London, UK; 2
Office of Health Economics, London, UK |
|
PMC4 |
CAN ECONOMIC
EVALUATIONS BE MADE MORE TRANSFERABLE?
Drummond MF1, Boulenger SM2, Rice
SJC3, Ulmann P4, Nixon J3, De
Pouvourville G5
1 University of York, York, North Yorkshire, UK;
2 College des Economistes de la Sante, Paris, Paris,
France; 3 University of York, YORK, North Yorkshire,
UK; 4 CNAM/CES, Paris, Paris, France; 5
INSERM U 537, Le Kremlin-Bicêtre, France |
|
PMC5 |
ARE THE BEST
AVAILABLE, MOST APPLICABLE CLINICAL EFFECTIVENESS DATA USED IN
ECONOMIC EVALUATIONS OF DRUG THERAPIES?
Drummond M1, Hanratty B2, Nixon J1,
Christie J1
1 University of York, York, North Yorkshire, UK;
2 University of Liverpool, Liverpool, Liverpool, UK |
|
PMC6 |
THE IMPORTANCE
OF ACCOUNTING FOR THE PORTFOLIO EFFECTS IN COST EFFECTIVENESS
ANALYSES
Bridges JFP
University of Heidelberg, Heidelberg, BW, Germany |
|
PMC7 |
UNIQUE USES OF
INSURANCE DATA RECORDS
Meyer J1,
Crown WH2, Grina M1
1 Ingenix, Eden Prairie, MN, USA; 2
Ingenix, Auburndale, MA, USA |
|
PMC8 |
OVER-THE-COUNTER PHENAZOPYRIDINE: AN ASSESSMENT OF CONSUMER
KNOWLEDGE
Shi CW
University of California, San Diego, La Jolla, CA, USA |
|
PMC9 |
HEALTH PROGRAM
IMPACT EVALUATION USING OBSERVED AND EXPECTED TIME SERIES OF
PHARMACEUTICAL CONSUMPTIONS
Menna A1, Marata AM1, Solfrini V2,
Magrini N1
1 Local Health Authority, Modena, Modena, Italy;
2 Local Health Authority, Bologna, Italy |
|
PMC10 |
ASP PLUS SIX
PERCENT IN 2005-A CONCEPTUAL VIEW OF FUTURE PHYSICIAN PAYMENTS
FOR DRUGS AND THEIR ADMINISTRATION IN THE OFFICE SETTING
Baker JJ
Resource Group, Ltd, Pickton, TX, USA |
|
PMC11 |
COMPARING
DIFFERENT APPROXIMATION METHODS FOR REMAINING LIFE EXPECTANCY IN
DECISION TREES
Siebert U, Conrads FA
Harvard Medical School, Boston, MA, USA |
|
PMC12 |
EVALUATING DRUG
SAFETY USING STOCHASTIC SIMULATION MODELS
Maguire A1, Arellano FM2,
Perez-Gutthan S1
1 Pfizer, Sant Cugat, Barcelona, Spain; 2
Risk Management Resources, Califon, NJ, USA |
|
PMC13 |
DEVELOPING THE
EUROPEAN NETWORK OF HEALTH ECONOMIC EVALUATIONS DATABASES
(EURONHEED): THE ACTIVITIES OF ONE CENTRE TO FULFILL BOTH
INTERNATIONAL AND LOCAL NEEDS
Redekop WK1, Van Nooten F1,
Bouwmans C1, Rutten F2, Koopmanschap MA3
1 Institute of Health Policy and Management,
Rotterdam, Netherlands; 2 Institute for Medical
Technology Assessment, Rotterdam, Netherlands; 3
Erasmus Medical Centre, Rotterdam, Netherlands |
|
PMC14 |
PERSONAL DRUG
UTILIZATION REPORT (PDUR) - A CONTRIBUTION TO COST REDUCTION AND
PATIENT EMPOWERMENT
Lentges N, Verheyen F, Hecke TL, Müller H
Techniker Krankenkasse, Hamburg, Germany |
|
PMC15 |
WEIGHING
DIAGNOSES IN EVALUATION STUDIES WITH AN APPLICATION TO SYNCOPE
Boer KR, Van Dijk N, Wieling W,
Dijkgraaf MGW
Academic Medical Center / University of Amsterdam, Amsterdam,
Netherlands |
|
PMC16 |
ANNUAL BURDEN
OF DRY EYE SYNDROME IN SIX EUROPEAN COUNTRIES
Clegg JP1, Guest JF1, Smith AF2
1 Catalyst Health Economics Consultants, Middlesex,
United Kingdom; 2 University of Oxford, Oxford,
United Kingdom |
|
PMC17 |
THERE'S NO F
IN UTILITY
Kind P
Outcomes Research Group, York, UK |
|
PMC18 |
STATISTICAL
ISSUES IN DISCRETE CHOICE MODELLING
Fitzgerald PE1, Aristides M2
1 M-TAG Pty Ltd, Chatswood West, New South Wales,
Australia; 2 M-TAG Ltd, London, UK |
|
PMC19 |
Withdrawn |
|
PMC20 |
DEVELOPMENT OF
A NUTRITION RELATED QUALITY OF LIFE SCALE IN CHILDREN
Artes M1, Muñoz A1, Cobo JM2,
Casas F3, Zaragoza S4, Cáceres M5
1 Adelphi Targis, Barcelona, Spain; 2
Danone, Barcelona, Spain; 3 Universidad de Girona,
Girona, Spain; 4 Psyncro, Barcelona, Spain; 5
Hospital General de Catalunya, Catalunya, Spain |
|
PMC21 |
AN EXPLORATION
OF THE DISCREPANCIES BETWEEN HEALTH STATE VALUATIONS OF PATIENTS
AND THE GENERAL POPULATION
Ratcliffe J, Brazier J, Palfreyman S, Michaels J
Sheffield University, Sheffield, UK |
|
PMC22 |
REVIEW OF
INSTRUMENTS MEASURING TREATMENT SATISFACTION WITH MEDICATION
Gandra SR1, Parasuraman B2,
Lawrence LW1, Humble LJ1
1 The University of Louisiana at Monroe, Monroe, LA,
USA; 2 AstraZeneca LP, Wilmington, DE, USA |
|
PMC23 |
REVIEW AND
ASSESSMENT OF THE ECONOMIC EVALUATION STUDIES ON HEALTH CARE IN
MEXICO
Bravo Ruiz ML1,
Soto Molina H2, Guzmán Vasquez S3, Arreola
Ornelas H2, Villasis MA2, Reynoso N N2,
Rely K2, Garduño Espinosa J2
1 Secretaria de Salud, Mexico D.F, Mexico D.F,
Mexico; 2 Instituto Mexicano Seguro Social, Mexico
D.F, Mexico D.F, Mexico; 3 Universidad del Estado De
México, Toluca, Estado de México, Mexico |
MENTAL HEALTH
Clinical Outcomes
Studies
|
PMH1 |
IMPACT OF
WEIGHT GAIN ON TREATMENT EFFECTIVENESS WITH OLANZAPINE OR
ARIPIPRAZOLE, CONSIDERING NON-ADHERENCE, RELAPSE AND COST OF
RELAPSE IN PATIENTS WITH SCHIZOPHRENIA IN FINLAND
Ruppert A1, Muhonen T2, Sinkkonen
T2
1 Bristol-Myers Squibb, Braine-l'Alleud, Belgium;
2 Bristol-Myers Squibb, Espoo, Finland |
|
PMH2 |
GEO
OBSERVATIONAL STUDY: 12 MONTH'S DISEASE CHARACTERISTICS, SIDE
EFFECTS AND SOCIOECONOMIC STATUS IN SCHIZOPHRENIA PATIENTS
TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY
Eichmann FRW1, Reitberger U1,
Clouth J2, Salize HJ3
1 Kendle International Inc, Munich, Germany; 2
Lilly Deutschland GmbH, Hamburg, Germany; 3
Zentralinstitut für Seelische Gesundheit, Mannheim, Germany |
Cost Studies
|
PMH3 |
FOLLOW-UP OF
SCHIZOPHRENIA PATIENTS DISCHARGED ON RISPERIDONE OR OLANZAPINE:
A TIME-TO-EVENT ANALYSIS
Adriaenssen I1, Rosillon D2,
Mehnert A3, Price M4, Ingham M1
1 Janssen Pharmaceutica N.V, Beerse, Belgium; 2
SGS Biopharma S.A, Wavre, Belgium; 3 Janssen Cilag,
Neuss, Germany; 4 Janssen-Cilag, High Wycombe,
Buckinghamshire, UK |
|
PMH4 |
THE COST OF
RELAPSE IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE
DISORDER IN AUSTRALIA; A RETROSPECTIVE AUDIT
Crowley S1, Kulkarni J2, Arya D3,
Fitzgerald P4, DeCastella A4, Meere S1
1 Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia;
2 Alfred Psychiatry Research Centre and Monash
University, Melbourne, VIC, Australia; 3 Fremantle
Hospital and University of Western Australia, Perth, WA,
Australia; 4 Alfred Psychiatry Research Centre,
Melbourne, VIC, Australia |
|
PMH5 |
FOLLOW-UP OF
SCHIZOPHRENIA PATIENTS DISCHARGED FROM PSYCHIATRIC HOSPITALS IN
THE UK ON RISPERIDONE OR OLANZAPINE: A TIME-TO-EVENT ANALYSIS
Price M1, Rosillon D2, Ingham M3,
Adriaenssen I3
1 Janssen-Cilag, High Wycombe, Buckinghamshire, UK;
2 SGS Biopharma S.A, Wavre, Belgium; 3
Janssen Pharmaceutica N.V, Beerse, Belgium |
|
PMH6 |
HEALTH EFFECTS
AND HEALTH CARE RESOURCE UTILIZATION IN POLISH SCHIZOPHRENIC
OUTPATIENTS INITIATING OR CHANGING TO OLANZAPINE OR TYPICAL
ANTIPSYCHOTIC MONOTHERAPY: ANALYSIS OF 12-MONTH DATA FROM SOHO
STUDY
Orlewska E1, Lis J2, Debowska G2
1 Centre for Pharmacoeconomics, Warsaw, Poland;
2 Eli Lilly, Warsaw, Poland |
|
PMH7 |
The
ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY AN
ELECTRONIC REGISTRY TO EVALUATE OUTCOMES DATA IN PATIENTS
Dominic Farmer1, Brecht Claerhout2, Angelika Mehnert3, Mike
Ingham3, An Jacobs3 on behalf of the e-STAR study group
1IES, UK, 2Custodix NV, Belgium, 3Janssen Pharmaceutica, Health
Economics, Belgium |
|
PMH8 |
COSTS AND
EFFECTS OF RISPERDAL CONSTA I IN COMPARISON TO CONVENTIONAL
DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN PORTUGAL
Heeg BM1, Buskens E1, Vaz Serra A2,
Pacheco Palha A3, Marques Teixeira J4,
Figueira L5, Jara J6, van Hout B1
1 PharMerit, Capelle a/d Ijssel, Netherlands; 2
Hospitais da Universidade de Coimbra, Coimbra, Portugal; 3
Hospital de Sao Joao, Oporto, Portugal; 4 Hospital de
Conde Ferreira, Oporto, Portugal; 5 Hospital de Sante
Maria, Lisbon, Portugal; 6 Hospital de Julio de
Matos, Lisbon, Portugal |
|
PMH9 |
A PROBABILISTIC
COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM, GENERIC CITALOPRAM
AND VENLAFAXINE AS A FIRST-LINE TREATMENT OF MAJOR DEPRESSIVE
DISORDER IN THE UK
Hemels ME1, Toumi I1, Wade AG2
1 H. Lundbeck A/S, Paris, France; 2 CPS
Research, Glasgow, UK |
|
PMH10 |
ECONOMIC
ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN NEW ZEALAND
Davies A1, Schrover R2, Crowley S2,
Neville AM3
1 Solutions for Health Ltd, Auckland, New Zealand;
2 Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia;
3 Pretium, Sydney, NSW, Australia |
|
PMH11 |
PROBABILISTIC
COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM VERSUS CITALOPRAM IN
THE TREATMENT OF SEVERE DEPRESSION IN THE UK
Hemels ME1, Toumi I1, Wade AG2
1 H. Lundbeck A/S, Paris, France; 2 CPS
Research, Glasgow, UK |
|
PMH12 |
THE IMPACT OF
PREMATURE DISCONTINUATION OF ANTIDEPRESSANT THERAPY IN MAJOR
DEPRESSIVE DISORDER IN THE UK
Beard SM1, Earnshaw SR2, Gaffney L1,
Hogue SL3, Krishnan AA3
1 RTI Health Solutions, Manchester, UK; 2
RTI Health Solutions, Raleigh-Durham, NC, USA; 3
GlaxoSmithKline, Raleigh-Durham, NC, USA |
|
PMH13 |
THE COST-
EFFECTIVENESS OF PAROXETINE IN TREATMENT OF MAJOR DEPRESSIVE
DISORDER IN JAPAN
Nakahara N1, Kamae I2, Yanagisawa
S2
1 Kobe University, Tokyo, Japan; 2 Kobe
University, Kobe, Japan |
|
PMH14 |
THE HEATLH
–RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE
COSTS TO SOCIETY
Hakkaart L1, Zwirs B2, Buitelaar J3,
Schulpen T2, Vlasveld L4, Bouwmans C1,
Rutten F1, Veraart C5
1 Institute for Medical Technology Assessment,
Rotterdam, Netherlands; 2 University Medical Center
Utrecht, Utrecht, Netherlands; 3 University Medical
Centre st Radboud Nijmegen; 4 Reinier de Graaf Group,
Delft; 5 Eli Lilly, The Netherlands |
|
PMH15 |
ANNUAL SOCIETAL
COSTS AND QUALITY OF LIFE IN CHILDREN WITH NEUROPSYCHIATRIC
DISORDERS IN SWEDEN
Myren KJ1, Gillberg C2, Nydén A2
1 Eli Lilly Sweden AB, Solna, Sweden; 2
Göteborg University, Gothenburg, Sweden |
|
PMH16 |
Withdrawn |
|
PMH17 |
COST-UTILITY
ANALYSIS OF MEDICAL CO-PRESCRIPTION OF HEROIN COMPARED WITH
METHADONE MAINTENANCE TREATMENT FOR CHRONIC, TREATMENT RESISTANT
HEROIN ADDICTS
Dijkgraaf MGW1, Van der Zanden BP1,
De Borgie CAJM1, Blanken P2, Van Ree JM2,
Van den Brink W1
1 Academic Medical Center / University of Amsterdam,
Amsterdam, Netherlands; 2 University Medical Centre
Utrecht, Utretch, Germany |
|
PMH30 |
COST-EFFECTIVENESS ANALYSIS IN THE AUSTRALIAN SETTING OF
RISPERIDONE LONG-ACTING INJECTION FOR THE TREATMENT OF PATIENTS
WITH SCHIZOPHRENIA WHO ARE PARTIALLY ADHERENT TO THEIR
MEDICATION
Crowley S1, Schrover R1, Neville
AM2
1 Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia;
2 Pretium, Sydney, NSW, Australia |
Quality of
Life/Utility/Preference Studies
|
PMH18 |
ASSESSING THE
TOTAL COST OF CARE FOR CEREBRAL PALSY PATIENTS WHO USE BOTULINUM
TOXIN TYPE A: AN APPROACH TO CONTROLLING BIAS IN CASE CONTROL
STUDIES
Dickson M1, Kozma C2, Barron R3
1 University of South Carolina, Columbia, SC, USA;
2 Independent Outcomes Consultant, West Columbia, SC,
USA; 3 Allergan Pharmaceuticals, Irvine, CA, USA |
|
PMH19 |
THE PERCEIVED
BENEFITS OF DOSING SCHEDULES FOR CHILDREN WITH ADHD
Price M1, Lloyd A2, Yuen C1,
Dewilde S2, Annemans L3, Coghill D4
1 Janssen-Cilag, High Wycombe, Buckinghamshire, UK;
2 MEDTAP International, London, UK; 3
HEDM, Meise, Belgium; 4 University of Dundee, UK |
|
PMH20 |
PATIENT-REPORTED OUTCOMES: DO THEY AGREE WITH OBJECTIVE
CAREGIVER-REPORTED OUTCOMES FOR INDIVIDUALS WITH SCHIZOPHRENIA
RESIDING IN THE COMMUNITY?
Barr J, Schumacher G, Ohman S, Mason E
Northeastern University, Boston, MA, USA |
|
PMH21 |
IS
HEALTH-RELATED QUALITY OF LIFE EVALUATION DIFFERENT BETWEEN
CLINICAL TRIALS AND OBSERVATIONAL STUDIES IN MAJOR DEPRESSIVE
DISORDER?
Sapin C, Le Lay A, Francois C
H. Lundbeck A/S, Paris, France |
Health Policy
Studies
|
PMH22 |
Withdrawn |
|
PMH23 |
ADHD TREATMENT
AND CO-MORBIDITIES: BASELINE RESULTS FROM THE OBSERVATIONAL
STUDY ADORE IN GERMANY
Rothenberger A1, Döpfner M2, Finnern H3,
Lorenzo M4, Ralston S4,
Dittmann R3
1 Georg-August-University Göttingen, Göttingen,
Germany; 2 University of Cologne, Cologne, Germany;
3 Lilly Deutschland GmbH, Bad Homburg, Germany;
4 Eli Lilly and Company Ltd, Windlesham, UK |
|
PMH24 |
EFFECT OF
ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIA
Joyce AT1, Ollendorf DA1, Harrison
DJ2, Cheli A2
1 PharMetrics Inc, Watertown, MA, USA; 2
Pfizer Inc, New York, NY, USA |
|
PMH25 |
EMERGENCY
DEPARTMENTS: THE FRONT LINE OF SCHIZOPHRENIA MANAGEMENT?
O'Brien JA, Pitoniak-Morse C, Duran P, Caro JJ
Caro Research Institute, Concord, MA, USA |
|
PMH26 |
SSRI
UTILIZATION AND PERSISTENCE IN A CALIFORNIA MEDICAID POPULATION
Nichol MB1, Shi SG1, Knight TK1,
Popovian R2
1 University of Southern California, Los Angeles, CA,
USA; 2 Pfizer, Inc, New York, NY, USA |
|
PMH27 |
THE EFFECT OF
RAISING THREE TIER CO-PAYMENTS ON SSRI ANTIDEPRESSANT COMPLIANCE
RATES
Mark TL1, Bron M2
1 Medstat, Washington, DC, USA; 2 Pfizer,
Inc, New York, NY, USA |
Methods
|
PMH28 |
METABOLIC
OUTCOMES OF ANTIPSYCHOTICS IN SCHIZOPHRENIA: A MARKOV MODEL
Sorensen SV1, Leaderer M2,
Harrison DJ2, Prasad M1, Hollenbeak CS1,
Revicki D1, Dugar A2, Cheli A2,
Remák E3
1 MEDTAP International Inc, Bethesda, MD, USA; 2
Pfizer Inc, New York, NY, USA; 3 MEDTAP International
Inc, London, UK |
MEN’S & WOMEN’S
HEALTH
Cost Studies
|
PMW1 |
ECONOMIC
EVALUATION OF THE ADMINISTRATION OF FOLLITROPIN-Â WITH A PEN
DEVICE COMPARED WITH ADMINISTRATION OF MENOTROPIN BY
CONVENTIONAL SYRINGE
Bruijnesteijn K1,
Van Genugten ML1, Hoomans E2,
Limbourg M3, Van Loon J1
1 Mapi Values, Houten, Netherlands; 2
Organon Nederlands BV, Oss, Noord Brabant, Netherlands; 3
Organon Belgium, Brussels, Belgium |
|
PMW2 |
HOW MUCH DOES
UNINTENDED PREGNANCY COST THE UK HEALTH CARE SYSTEM?
Sonnenberg F1,
Price M2, Neslusan C3
1 UMDNJ Robert Wood Johnson Medical School, New
Brunswick, NJ, USA; 2 Janssen-Cilag, High Wycombe,
Buckinghamshire, UK; 3 Johnson & Johnson
Pharmaceutical Services, New Brunswick, NJ, USA |
|
PMW3 |
IMPROVING THE
DELIVERY OF CHILD AND MATERNAL HEALTH CARE IN A POOR SETTING:
COSTS AND BARRIERS TO BE CONSIDERED IN THE IMPLEMENTATION OF WHO
MOTHER-BABY PACKAGE IN MORELOS, MEXICO
Cahuana L1, Sosa S2, Bertozzi S1
1 National Institute of Public Health, Cuernavaca,
Morelos, Mexico; 2 University of York, Heslington,
York, UK |
Quality of
Life/Utility/Preference Studies
|
PMW4 |
VALIDATION OF
THE SPANISH VERSION OF THE SELF-ESTEEM AND RELATIONSHIP (SEAR)
QUESTIONNAIRE FOR MEN WITH ERECTILE DYSFUNCTION (ED)
Rejas J1, Cabello F2, Calle A3,
Chantada V4, Forà F5, Garcia-Garcia M6,
Rico-Villademoros F7,
Martínez-Sánchez EM1
1 Pfizer SA, Alcobendas, Madrid, Spain; 2
Instituto Andaluz de Sexología, Málaga, Spain; 3
Hospital Clínico San Carlos, Madrid, Spain; 4
Hospital Juan Canalejo, La Coruña, Spain; 5 Centro
Médico Teknon, Barcelona, Spain; 6 Biométrica CRO,
Barcelona, Spain; 7 Biométrica CRO, Madrid, Spain |
|
PMW5 |
INFERTILITY
TREATMENT POLICIES IN GERMANY AND THE UK - WILLINGNESS TO PAY
AMONG AFFECTED COUPLES
Kilgert K, Smala A, Berger K
MERG Medical Economics Research Group, München, Germany |
|
PMW6 |
SHORT-TERM AND
LONG-TERM PSYCHOSOCIAL CONSEQUENCES OF FALSE POSITIVE SCREENING
MAMMOGRAPHY – DEVELOPMENT OF TWO NEW QUESTIONNAIRE BASED ON THE
PSYCHOLOGICAL CONSEQUENCES QUESTIONNAIRE (THE PCQ)
Brodersen J, Thorsen H, Andersen JS
Copenhagen University, Copenhagen, Denmark |
NEUROLOGICAL
DISORDERS
Clinical Outcomes
Studies
|
PNL1 |
PREVALENCE,
HEALTH RESOURCES USAGE AND COST OF VASCULAR DEMENTIA IN
COMPARISON WITH ALZHEIMER DISEASE IN A POPULATION SETTING IN
SPAIN
Sicras A1,
Rejas J2, Arco S3, Flores E4,
Ortega G5, Esparcia A5, Suárez A3,
Gordillo MJ4
1 Badalona Gestió Assistencial, SL, Badalona,
Barcelona, Spain; 2 Health Outcomes Research, Medical
Unit, Pfizer SA, Alcobendas, Madrid, Spain; 3 Area
Básica de Salud Apenins-Montigalà, Badalona, Barcelona, Spain;
4 Area Básica de Salud Morera-Pomar, Badalona,
Barcelona, Spain; 5 Area Básica de Salud
Tiana-Montgat, Montgat, Barcelona, Spain |
|
PNL2 |
STROKE SEVERITY
AND EARLY OUTCOMES AFTER FIRST-EVER ISCHEMIC STROKE
Tseng MC1, Chang KC2
1 National Sun Yat-Sen University, Kaohsiung, Taiwan;
2 Chang Gung Memorial Hospital, Kaohsiung, Taiwan |
Cost Studies
|
PNL3 |
PREDICTORS FOR
DIRECT AND INDIRECT COSTS IN PARKINSON’S DISEASE
Siebert U1, Bornschein B2, Spottke
EA3, Berger K4, Oertel WH5,
Dodel R3
1 Harvard Medical School, Boston, MA, USA; 2
University of Munich, Munich, Germany; 3 University
of Bonn, Bonn, Germany; 4 MERG Medical Economics
Research Group, Munich, Germany; 5 University of
Marburg, Marburg, Germany |
|
PNL4 |
NEW
LEVODOPA/CARBIDOPA/ENTACAPONE (STALEVO®) RESULTS IN
BETTER QUALITY OF LIFE FOR PARKINSON´S DISEASE PATIENTS AND
SAVES COSTS TO THE SOCIETY
Findley L1,
Turunen H2, Apajasalo M2, Lees A3
1 Oldchurch Hospital, Essex, UK; 2 Orion
Pharma, Espoo, Finland; 3 Reta Lila Weston Institute
of Neurological Studies, London, UK |
|
PNL5 |
SOCIAL COSTS OF
PARKINSON DISEASE IN ITALY
Zecchinelli A1, Caprari F2,
Ponzi P2, Bonetti A1, Pezzoli G1
1 Istituti Clinici di Perfezionamento, Milano, Italy;
2 Fondazione Medtronic Italia, Milano, Italy |
|
PNL6 |
THE HOSPITAL
COSTS OF PRIMARY STROKE PATIENTS MANAGEMENT IN POLAND
Niewada M1, Czonkowska A2,
Czonkowski A1, £atek M3, Kamiñski B3
1 Medical University of Warsaw, Warsaw, Poland;
2 Institute of Psychiatry and Neurology, Warsaw, Poland;
3 Warsaw School of Economics, Warsaw, Poland |
|
PNL7 |
COSTS OF STROKE
UNIT CARE IN GERMANY
Back T1, Haacke C2, Spottke EA3,
Schöffski O4, Dodel R3
1 Marburg University, Marburg, Germany; 2
University of Marburg; 3
Friedrich-Wilhelms-University, Bonn, Germany; 4
University of Erlangen |
|
PNL8 |
COST-EFFECTIVENESS OF THROMBOLYSIS WITH RT-PA FOR ACUTE ISCHEMIC
STROKE IN TAIWAN
Tseng MC1, Chang KC2
1 National Sun Yat-Sen University, Kaohsiung, Taiwan;
2 Chang Gung Memorial Hospital, Kaohsiung, Taiwan |
|
PNL9 |
INDIRECT COSTS
ASSOCIATED TO INSOMNIA IN OCCUPATIONAL HEALTH: THE SISYPHE STUDY
Godet-Cayré V1,
Pelletier-Fleury N1, Leger D2,
Dinet J3, Massuel MA3
1 INSERM, Le Kremlin-Bicêtre, France; 2
Centre de Sommeil Hôtel Dieu de Paris, Paris, France; 3
Sanofi-Synthelabo France, Le Plessis Robinson, France |
|
PNL10 |
THE
SOCIOECONOMIC IMPACT OF NARCOLEPSY
Dodel R1, Peter H2, Walbert T3,
Spottke EA1, Berger K4, Siebert U5,
Kesper K6, Becker H6, Mayer G7
1 Friedrich-Wilhelms-University, Bonn, Germany;
2 Philipps University, Marburg, Germany; 3
University of Bonn, Bonn, Germany; 4 MERG Medical
Economics Research Group, München, Germany; 5 Harvard
Medical School, Boston, MA, USA; 6 Marburg
University, Marburg, Germany; 7 Hephata Kliniken,
Schwalmstadt-Treysa, Germany |
|
PNL11 |
EFFECT OF
COMORBIDITIES ON MEDICAL CARE USE AND COST AMONG PATIENTS WITH
PARTIAL SEIZURE DISORDER
Lee WC1, Arcona S2, Thomas SK2,
Wang Q1, Hoffmann MS1, Botteman MF1,
Pashos CL3
1 Abt Associates Inc, Bethesda, MD, USA; 2
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;
3 Abt Associates Inc, Cambridge, MA, USA |
|
PNL12 |
HEALTHCARE
UTILIZATION AND SOCIOECONOMIC ASPECTS OF NEUROMUSCULAR DISEASES
Spottke EA1, Mylius V2, Claus D3,
Grothe C1, Heuss D4, Kiefer R5,
Klockgether T1, Schrank B6, Schröder R1,
Vielhaber S7, Walbert T1, Dodel R1,
Schepelmann K2
1 Friedrich-Wilhelms-University, Bonn, Germany;
2 Philipps-University, Marburg, Germany; 3
Clinic Darmstadt, Darmstadt, Germany; 4 University
Erlangen, Erlangen, Germany; 5 University Muenster,
Muenster, Germany; 6 Clinic of Diagnostics,
Wiesbaden, Germany; 7 Otto-von-Guericke University,
Magdeburg, Germany |
|
PNL13 |
PROFILE OF
PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME AND ESTIMATION OF
THEIR ANNUAL COST IN AN AMBULATORY CARE SETTING, IN FRANCE
Maurel F1, Girard B1, Crochard A2,
Henri M2, El Hasnaoui A2, Le Pen C3
1 Aremis Consultants, Paris, France; 2
GlaxosmithKline, France; 3 Aremis Consultants and
Paris Dauphine University, Paris, France |
|
PNL14 |
THE
COST-EFFECTIVENESS OF TREATING PATIENTS WITH RESTLESS LEGS
SYNDROME (RLS) USING ROPINIROLE
Moore AP1, Lloyd A2, Scott DA2,
Connolly M3, Dixon S4
1 The Walton Centre for Neurology and Neurosurgery,
Liverpool, UK; 2 Fourth Hurdle; 3
GlaxoSmithKline, London, Middlesex, UK; 4 Sheffield
University, Sheffield, South Yorkshire, UK |
|
PNL15 |
RETROSPECTIVE
EVALUATION OF THE DOSE OF DYSPORTÒ AND BOTOXÒ IN THE CLINICAL
MANAGEMENT OF CERVICAL DYSTONIA OR BLEPHAROSPASM – THE REAL DOSE
STUDY EXPANSION – COST CONSIDERATIONS BASED ON DRUG START
Magar R1, Ahmed F2, Findley L3,
Larsen JP4, Pirtosek Z5, Slawek J6,
Rùžièka E7
1 Thomson Corporation, Secaucus, NJ, USA; 2
Hull Royal Infirmary, UK; 3 Essex Neuroscience Unit,
UK; 4 Central Hospital of Rogaland, Norway; 5
University Clinical Centre, Slovenia; 6 St. Adalbert
Hospital, Poland; 7 Charles University, Czech
Republic |
|
PNL16 |
A COMPARATIVE
STUDY ON RESOURCE USE, COSTS AND CAREGIVER BURDEN BETWEEN
RASAGILINE AND ENTACAPONE IN FLUCTUATING PARKINSON'S DISEASE
(PD) PATIENTS
Roch B1, Despiegel N2, François C1,
Goren T3
1 H. Lundbeck A/S, Paris, France; 2
H.Lundbeck A/S, Paris, France; 3 Teva
Pharmaceuticals, Petach Tikva, Israel |
|
PNL17 |
MARKOV MODEL OF
ADJUNCTIVE ANTIEPILEPTIC TREATMENT FOR CHILDREN - A COMPARISON
OF TOPIRAMATE AND LAMOTRIGINE
Remák E1, Hutton J1, Price M2,
Peeters K3, Adriaenssen I3
1 MEDTAP International Inc, London, UK; 2
Janssen-Cilag, High Wycombe, UK; 3 Johnson & Johnson
Pharmaceutical Services, Beerse, Belgium |
|
PNL18 |
COSTS AND
OUTCOMES ASSOCIATED WITH THE USE OF BOTULINUM TOXIN TYPE A
(BTX-A) IN THE TREATMENT OF FLEXED WRIST/CLENCHED FIST
POST-STROKE SPASTICITY
Christensen TL1, Poulsen PB1,
Holmström S2
1 Muusmann Research & Consulting, Kolding, Denmark;
2 Allergan R&D Europe, Mougins-Cedex, France |
|
PNL31 |
HEALTHCARE
RESOURCES USED BY SPANISH PRIMARY CARE PHYSICIANS IN PATIENTS
WITH SUBJECTIVE MEMORY COMPLAINTS OR COGNITIVE IMPAIRMENT. THE
ISSEA STUDY
Badia X1, Argimón JM2,
Martínez-Lage JM3, Riu S4, Lara N1
1 Health Outcomes Research Europe Group, Barcelona,
Spain; 2 Regió Sanitària Costa de Ponent.Catsalut;
3 Unidad de Transtornos de Memoria. Clínica
Universitaria de Navarra, Pamplona, Spain; 4 Unitat
de Psicogeriatria. Centre geriàtric, Llars Mundet, Barcelona,
Spain |
Quality of
Life/Utility/Preference Studies
|
PNL19 |
VALIDATING THE
RESTLESS LEGS SYNDROME QUALITY OF LIFE QUESTIONNAIRE (RLSQOL) IN
A TRIAL PATIENT POPULATION
Abetz L1, Arbuckle R2, Allen R3,
Mavraki E4, Kirsch J4
1 Mapi Values Ltd, Macclesfield, Cheshire, UK; 2
Mapi Values Ltd; 3 Johns Hopkins Bayview Medical
Center, Baltimore, MD, USA; 4 GlaxoSmithKline
Research and Development, Research Triangle Park, NC, USA |
|
PNL20 |
A SIMPLIFIED
SEVERITY SCALE FOR THE ASSESSMENT OF RESTLESS LEGS SYNDROME :
THE DESYR STUDY GROUP
Montplaisir J1, Crochard A2,
Arnulf I3, Huas D4, Krieger J5,
Lainey E6, Leger D7, Pouchain D2,
Tison F8, Schwalm M9, Schuck S10,
El Hasnaoui A2
1 Hopital du Sacré-Coeur, Montreal, QC, Canada;
2 GlaxoSmithKline, Les Ulis, France; 3 Hopital
de la Pitié-Salpétrière, Paris, France; 4 Université
Xavier Bichat, Paris, France; 5 Université Louis
Pasteur, Strasbourg, France; 6 Hopital européen
Georges Pompidou, Paris, France; 7 Hotel dieu, Paris,
France; 8 Université de Bordeaux 1, Talence, France;
9 BKL Thalès, Paris, France; 10 Kappa
Santé, Paris, France |
|
PNL21 |
INDEPENDENT
EFFECT OF DYSKINESIA ON HEALTH-RELATED QUALITY OF LIFE IN
PATIENTS WITH PARKINSON’S DISEASE – A MULTIVARIATE ANALYSIS
Siebert U1, Bornschein B2, Dodel R3,
Competence Network Parkinson Syndromes C4
1 Harvard Medical School, Boston, MA, USA; 2
University of Munich, Munich, Germany; 3 University
of Bonn, Bonn, Germany; 4 University of Marburg,
Marburg, Germany |
|
PNL22 |
EFFECT OF
DISEASE-SPECIFIC COMPLICATIONS ON THE PREDICTION OF UTILITIES IN
PARKINSON’S DISEASE
Siebert U1, Bornschein B2, Spottke
EA3, Dodel R3
1 Massachusetts General Hospital, Harvard Medical
School, Boston, MA, USA; 2 University of Munich,
Munich, Germany; 3 University of Bonn, Bonn, Germany |
|
PNL23 |
CHRONIC
NEUROPATHIC PAIN (NEP)
IMPACT ON PATIENT QUALITY OF LIFE AND DISABILITY: RESULTS FROM
THE DONEGA STUDY
Gálvez R1, Ribera MV2, Rejas J3,
Masramón X4,
Ruíz M3
1 Pain & Palliative Care Unit, Hospital Virgen de las
Nieves, Granada, Spain; 2 Pain Unit, Hospital Vall
d´Hebrón, Barcelona, Spain; 3 Pfizer SA, Alcobendas,
Madrid, Spain; 4 Euroclin Institute, Barcelona, Spain |
|
PNL31 |
NEUROPATHIC PAIN (NEP)
IMPACT ON PATIENT MENTAL FUNCTIONING, SYMPTOM LEVELS OF ANXIETY
AND DEPRESSION, AND SLEEP DISTURBANCE: RESULTS FROM THE DONEGA
STUDY
Gálvez R1,
Ribera MV2, Rejas J3, Masramón X4,
Ruíz M3
1 Pain & Palliative Care Unit, Hospital Virgen de las
Nieves, Granada, Spain; 2 Pain Unit, Hospital Vall
d´Hebrón, Barcelona, Spain; 3 Pfizer SA, Alcobendas,
Madrid, Spain; 4 Euroclin Institute, Barcelona, Spain |
Health Policy
Studies
|
PNL24 |
COMPARING
CLASSIFICATION AND REGRESSION TREE ANALYSIS WITH MULTIPLE
REGRESSION FOR TRANSLATING A CLINICAL PARKINSON'S DISEASE SCALE
INTO UTILITIES
Siebert U1, Bornschein B2, Dodel R3
1 Harvard Medical School, Boston, MA, USA; 2
University of Munich, Munich, Germany; 3 University
of Bonn, Bonn, Germany |
|
PNL25 |
INTERNAL,
EXTERNAL, AND CROSS-MODEL VALIDATION OF A MULTI-OUTCOME DECISION
MODEL FOR PARKINSON'S DISEASE
Siebert U1, Bornschein B2, Dodel R3
1 Harvard Medical School, Boston, MA, USA; 2
University of Munich, Munich, Germany; 3
Friedrich-Wilhelms-University, Bonn, Germany |
|
PNL26 |
A NEW SCREENING
TOOL FOR MIGRAINE IN THE GENERAL POPULATION: THE
MIGRAINE-SCREEN-Q (MS-Q)
Láinez JM1, Domínguez M2, Arriaza
E3, Palacios G3, Madrigal M3,
Garcia-Garcia M4, Rejas J3
1 University Hospital, Valencia, Spain; 2
Hospital Puerta de Hierro, Madrid, Spain; 3 Pfizer
SA, Alcobendas, Madrid, Spain; 4 Biométrica CRO,
Barcelona, Spain |
|
PNL27 |
MAPPING THE
INTERNATIONAL RESTLESS LEGS SYNDROME RATING SCALE (IRLS) TO THE
EQ-5D BY FOUR CLINICIANS
Loftus JV1, Connolly M1, Allen R2,
Garcia-Borreguero D3, Billiard M4,
Tidswell P5
1 GlaxoSmithKline, London, Middlesex, UK; 2
Neurology and Sleep Medicine, Baltimore, MD, USA; 3
Fundacion Jiminez Diaz, Madrid, Spain; 4 Gui de
Chauliac, Montpelier, Cedex 5, France; 5 Chorley
Clinic Research Centre, Chorley, Lancashire, UK |
|
PNL28 |
CENTERED
REGRESSION FUNCTIONS AS A TECHNIQUE TO IMPROVE FLEXIBILITY AND
TRANSFERABILITY OF MARKOV MODELS
Siebert U1, Bornschein B2, Dodel R3
1 Harvard Medical School, Boston, MA, USA; 2
University of Munich, Munich, Germany; 3 University
of Bonn, Bonn, Germany |
|
PNL29 |
ESTIMATING THE
COST OF ILLNESS IN EUROPE – A MODEL WITH MULTIPLE SCLEROSIS AS
AN EXAMPLE
Andlin-Sobocki P1, Kobelt G2,
Pugliatti M3, Jönsson B4
1 Karolinska Institute, Stockholm, Sweden; 2
European Health Economics SAS, Spéracèdes, France; 3
University of Sassari, Sassari, Italy; 4 Center for
Health Economics, Stockholm School of Economics, Stockholm,
Sweden |
PITUITARY GLAND
DISORDERS
Cost Studies
|
PPT1 |
COST-OF-ILLNESS
STUDY IN ACROMEGALIC PATIENTS IN ITALY
Didoni G1, Ghigo E2, Minuto F3
1 Pfizer Italia srl, Rome, Italy; 2
Molinette Hospital, Turin, Italy; 3 University of
Genoa, Genoa, Italy |
Quality of
Life/Utility/Preference Studies
|
PPT2 |
THE DEFICIT IN
HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR GROWTH HORMONE
DEFICIENT (GHD) PATIENTS IN SPAIN AND ENGLAND & WALES: A
COMPARISON WITH NORMATIVE POPULATION DATA
Mattsson A1, Casanueva F2,
Espadero R3, Bada X4, Sanmarti A5,
Kind P6, Koltowska-Häggström M1
1 Pfizer Health AB, Stockholm, Sweden; 2
University of Santiago de Compostela, Santiago de Compostela,
Spain; 3 Pfizer, Madrid, Spain; 4 Health
Outcomes Research Europe, Barcelona, Spain; 5
Hospital Germans Trias i Pujol, Badalona, Spain; 6
University of York, York, UK |
URINARY/KIDNEY
DISEASES DISORDERS
Cost Studies
|
PUK1 |
THE
COST-EFFECTIVENESS OF EXTENDED RELEASE TOLTERODINE IN THE
MANAGEMENT OF OVERACTIVE BLADDER IN GERMANY AND THE UNITED
KINGDOM
Anderson P1, Resch A2, Dooley JA3,
Bruggenjurgen B4, Zlateva G5
1 Fourth Hurdle Consulting Ltd, London, UK; 2
Pfizer GmBH, Karlsruhe, Germany; 3 Pfizer Ltd,
Tadworth, UK; 4 Alpha Care GmbH, Celle, Germany;
5 Pfizer, Inc, New York, NY, USA |
|
PUK2 |
COST-EFFECTIVENESS ANALYSIS OF EXTENDED-RELEASE TOLTERODINE
VERSUS IMMEDIATE-RELEASE TOLTERODINE IN THE MANAGEMENT OF
OVERACTIVE BLADDER IN SPAIN
Castro D1,
Soto J2, Exposito I2
1 Hospital Universitario de Canarias, La Laguna,
Tenerife, Spain; 2 Pfizer S.A, Alcobendas, Madrid,
Spain |
|
PUK3 |
ECONOMIC
ASSESSMENT OF URO-VAXOM® IN FEMALE PATIENTS WITH RECURRENT
URINARY TRACT INFECTION IN GERMANY
Brüggenjürgen B1, Cozma G2
1 Alpha Care GmbH, Celle, Germany; 2 OM
PHARMA, Meyrin, Switzerland |
|
PUK4 |
PATIENT
PERCEPTION OF OAB DRUG THERAPY SUCCESS IS ASSOCIATED WITH LESS
HEALTHCARE RESOURCE USE
Cerulli A1, Kahler K1, Banfe E2,
Gause D1
1 Novartis Pharmaceuticals Corporation, East Hanover,
NJ, USA; 2 Consumer Health Sciences, Princeton, NJ,
USA |
|
PUK5 |
ECONOMIC
VALUATION OF THE EFFECTS OF DIETARY PROTEIN RESTRICTION ON THE
PROGRESSION OF CHRONIC RENAL DISEASE
Di Stasi F1, Monzini MS1,
Colasanti G2, Luperini M2, Arrigo G2,
Mantovani LG1
1 University of Milan, Milan, Italy; 2
Azienda Ospedaliera “Ospedale S. Carlo Borromeo”, Milan, Italy |
|
PUK6 |
COST OF RENAL
TRANSPLANTATION IN BELGIUM
Lecomte P1, Chaib Eddour D2,
Squifflet JP2
1 Novartis Pharma, Vilvoorde, Brussels, Belgium;
2 Cliniques UCL Saint-Luc, Brussels, Belgium |
|
PUK7 |
WHEN SHOULD
ERYTHROPOIETIN (EPO) BE REPLACED BY PACKED RED BLOOD CELL
TRANSFUSION (TR) IN HEMODIALYSIS (HD) PATIENTS?
Kuehne FC1,
Stoffel MP2, Barth C3, Baldamus CA4
1 PharmacoConsult, Wanzleben, Germany; 2
KfH, Cologne, Germany; 3 KfH, Neu-Isenburg, Germany;
4 University Cologne, Cologne, Germany |
|
PUK8 |
2-HOUR POST
DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL: AN
ECONOMIC EVALUATION
Hagenmeyer EG1, Häussler B1,
Balshaw R2, Keown P3, Kilburg A4,
Kaló Z5, Nashan B6
1 IGES Institut für Gesundheits- u. Sozialforschung,
Berlin, Germany; 2 Simon Fraser University and Syreon
Corp; 3 Department of Medicine, University of British
Columbia; 4 Novartis Pharma AG; 5 Novartis
Hungary Ltd; 6 Dalhousie University Halifax |
|
PUK9 |
EVALUATION OF
THE COST UTILITY OF SIROLIMUS VERSUS TACROLIMUS FOR
IMMUNOSUPPRESSION FOR RENAL TRANSPLANTATION IN THE UK
Currie CJ1, Dixon S2, Conway P3,
McEwan P4
1 Cardiff Research Consortium, Cardiff, Wales, UK;
2 Sheffield University, Sheffield, South Yorkshire,
UK; 3 Wyeth UK, Maidenhead, UK; 4 Cardiff
University, Cardiff, Wales, UK |
|
PUK10 |
A HEALTH
ECONOMIC EVALUATION OF 6 MONTHS ALFUZOSIN TREATMENT IN THE
MANAGEMENT OF ACUTE URINARY RETENTION
Lamotte M, Cleemput I, Annemans L
HEDM, Meise, Belgium |
|
PUK11 |
COST-CONSEQUENCES OF TREATING WOMEN WITH STRESS URINARY
INCONTINENCE WITH DULOXETINE FROM THE PERSPECTIVE OF THE
STATUTORY HEALTH INSURANCE IN GERMANY
Papanicolaou S1, Andlin-Sobocki P2,
Thüroff J3, Graf v.d. Schulenburg J-M4,
Blanke M4, Finnern H5, Sykes D1
1 Eli Lilly and Company Ltd, Windlesham, Surrey, UK;
2 Stockholm Health Economics AB, Stockholm, Sweden;
3 Johannes Gutenberg University Mainz, Mainz,
Germany; 4 University of Hannover, Hannover, Germany;
5 Lilly Deutschland GmbH, Bad Homburg, Germany |
|
PUK12 |
LONG-TERM
COST-EFFECTIVENESS MODELLING OF FEEDBACK MICROWAVE THERMOTHERAPY
VERSUS DRUG TREATMENT IN PATIENTS WITH BENIGN PROSTATIC
HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS
Hjelmgren J1, Malmberg L2,
Ragnarson-Tennvall G1
1 The Swedish Institute for Health Economics (IHE),
Lund, Sweden; 2 Lund University Hospital, Lund,
Sweden |
Quality of
Life/Utility/Preference Studies
|
PUK13 |
LOWER MENTAL
HEALTH SCORES MEASURED USING THE SF-36 HEALTH SURVEY IS AN
INDEPENDENT PREDICTOR OF MORTALITY IN YOUNGER PATIENTS RENAL
REPLACEMENT THERAPY
García-Mendoza M, Valdés C, Rebollo P, Ortega T, Ortega
F
Hospital Universitario Central de Asturias Institute, Oviedo,
Spain |
|
PUK14 |
ELDERLY
PATIENTS STARTING RENAL REPLACEMENT THERAPY (RRT) HAVE LOWER
LOSS OF HEALTH RELATED QUALITY OF LIFE (HRQL) THAN YOUNGER ONES
DURING THE FIRST TWO YEARS
García-Mendoza M, Valdés C, Ortega T, Rebollo P, Ortega
F
Hospital Universitario Central de Asturias Institute, Oviedo,
Spain |
|
PUK15 |
PATIENTS
UNDERGOING PERITONEAL DIÁLISIS HAVE BETTER PERCEIVED HEALTH IN
SEVERAL SPECIFIC PROBLEMS RELATED WITH RENAL DISEASE THAN
PATIENTS UNDERGOING HEMODIALYSIS
Valdés C1, Alvarez-Ude F2, Rebollo
P1, Estebanez C2
1 Hospital Universitario Central de Asturias
Institute, Oviedo, Spain; 2 Hospital General de
Segovia Instutute, Segovia, Spain |
|
PUK16 |
VALIDATION OF
TWO QUESTIONNAIRES ON SYMPTOMS AND QUALITY OF LIFE IN ITALIAN
WOMEN WITH LUTS: THE FLOW STUDY
Simoni L1, Rizzi CA2, Santini A2,
Sgarbi S1, Tubaro A3, Prezioso D4,
Zattoni F5, Artibani W6, Pesce F6,
Scarpa RM7
1 MediData srl, Modena, Italy; 2
Boehringer Ingelheim, Milan, Italy; 3 Hospital S.
Andrea, Roma, Italy; 4 University “Federico II”,
Naples, Italy; 5 Az Osp S.M. Misericordia, Udine,
Italy; 6 Policlinico G. Rossi, Verona, Italy; 7
University of Torino, Turin, Italy |
|
PUK17 |
EVALUATION OF
TREATMENT OF FEMALE URINARY INCONTINENCE WITH THE ICIQ-UI SF
QUESTIONNAIRE
Espuña M1, Rebollo P2, Puig M1
1 Hospital Clinic i Provincial. Universidad de
Barcelona, Barcelona, Catalonia, Spain; 2 Hospital
Universitario Central de Asturias, Oviedo, Asturias, Spain |
|
PUK18 |
VALIDATION OF A
PATIENT-ADMINISTERED QUESTIONNAIRE TO MEASURE ACTIVITY
IMPAIRMENT AS A RESULT OF UNCOMPLICATED URINARY TRACT INFECTION:
THE ACTIVITY IMPAIRMENT ASSESSMENT (AIA)
Wild DJ1, Clayson DJ1, Keating K2,
Gondek K2
1 Oxford Outcomes Ltd, Oxford, Oxon, UK; 2
Bayer HealthCare Pharmaceuticals, West Haven, CT, USA |
|
PUK19 |
DEVELOPMENT OF
A QUESTIONNAIRE TO ASSESS QUALITY OF CARE IN DUTCH DIALYSIS
CENTRES
Oppe M, Weijnen TJG,
de Charro FT
Erasmus University Rotterdam, Rotterdam, Netherlands |
|
PUK24 |
PREVALENCE AND QUALITY OF LIFE IN
FRENCH WOMEN WITH STRESS URINARY INCONTINENCE
Gasquet I1, Klein P2,
Gaudebout P3, Alfonsi A4,
Tcherny S4, Haab F5
1 Paul Brousse Hospital - AP-HP, Villejuif, France;
2 IPSOS, Paris, France; 3 AP-HP, Paris,
France; 4 LILLY France, Suresnes, France; 5
Tenon Hospital, Paris, France |
Health Policy
Studies
|
PUK20 |
IMPLICATIONS OF
OVERACTIVE BLADDER ICD-9 CODE CHANGES AND USE OF CODES IN A
MANAGED CARE POPULATION
Nitz NM1, Jumadilova Z2, Meyer J1,
Bavendam T2
1 Ingenix Pharmaceutical Services, Eden Prairie, MN,
USA; 2 Pfizer, Inc, New York, NY, USA |
|
PUK21 |
AN ANALYSIS OF
PATIENTS ON WAITING LISTS TO RECEIVE SURGERY FOR STRESS URINARY
INCONTINENCE (SUI) IN ENGLAND AND SCOTLAND
McAllister R1,
Das Gupta R2, Piercy J3, Ryan J1
1 Mapi Values Ltd, Macclesfield, Cheshire, UK; 2
Boehringer-Ingelheim, Bracknell, UK; 3 Adelphi Group,
UK |
Methods
|
PUK22 |
DERIVING UNIT
COSTS FOR RESOURCE UTILISATION IN PROSPECTIVE URINARY
INCONTINENCE RESEARCH (PURE) - AN OBSERVATIONAL STUDY IN 14
EUROPEAN COUNTRIES
Papanicolaou S1, Davies A2,
Espuña-Pons M3, Hampel C4, Hunskaar S5,
Monz B6, Samsioe G7, Wagg A8,
Sykes D9
1 Eli Lilly and Company Limited, Windlesham, Surrey,
UK; 2 MEDTAP International, London, UK; 3
University Hospital of Barcelona, Spain; 4 University
Hospital of Mainz, Germany; 5 University of Bergen,
Norway; 6 Boehringer Ingelheim GmbH, Ingelheim,
Germany; 7 Lunds University Hospital, Sweden; 8
University College Hospital, London, UK; 9 Eli Lilly
and Company Limited, Windlesham, UK |
|
PUK23 |
LANTHANUM
CARBONATE FOR THE TREATMENT OF HYPERPHOSPHATAEMIA: DEVELOPMENT
OF A COST-EFFECTIVENESS MODEL
Brennan A, Akehurst R, Davis S, Sakai H
School of Health and Related Research, University of Sheffield,
Sheffield, UK |
7th Annual European Congress Main Page
|
